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Herpes simplex virus type 2 (HSV-2) is a highly infectious pathogen that causes genital ulcerative 
disease and it affects millions of people worldwide. ACAM529 is a promising new live replication-
deficient vaccine candidate against the virus. Vaccine stability during the upstream production 
processes is an issue so there is a great need for developing an effective stabilization buffer that will 
protect the vaccine during the process. The purpose of this work was to study the characteristics of 
ACAM529 and identify excipients that would protect the vaccine from inactivation in liquid solution 
short-term.  
To establish a baseline of ACAM529 stability for further improvements, three lots of purified 
ACAM529 with differing purification protocols were characterized: Lot A, Lot B and Lot C. Plaque 
assays were used to determine the titer of each lot, SDS-PAGE was used to analyze the albumin 
content, and transmission electron microscopy (TEM) was used to image the virus. Lot C was found 
to have the highest titer at 5.2 ± 0.6 x 107 PFU/ml and albumin concentration at approximately 8 g/L 
compared to Lot A (3.4 ± 0.6 x 106 PFU/ml and 0.5-1 g/L, respectively) and Lot B (2.1 ± 0.4 x 107 
PFU/ml and <0.13 g/L, respectively). TEM imaging revealed a high prevalence of unenveloped 
compared to enveloped virus and some clumping of virus particles, however no differences could be 
identified between the lots. In addition, a time course assay was developed to study the stability of 
ACAM529 over 120h. Lot C was found to be more stable than Lot A and Lot B, especially at lower 
temperatures. Lot A and Lot B showed similar levels of stability at 2-4°C and 25°C. 
To screen for ACAM529 stabilizers in liquid solution, various defined and complex solutions used in 
cell culture for virus production were studied using a time course assay. The addition of 0.01%-10% 
FBS to the reference buffer resulted in improvements to Lot B stability at 27°C, with minimal titer 
loss after 120h occurring with 1% FBS. The addition of 0.05-5 g/L rHSA to the reference buffer for 
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Lot B improved viral stability at 2-4°C in a concentration-independent manner. However, at 27°C, 
0.5-5 g/L rHSA significantly reduced the stability, where increasing concentrations of rHSA lead to 
decreasingly stable virus. Low concentrations of rHSA (0.05 g/L) improved stability at 27°C. The 
addition of 10% conditioned OptiPro SFM resulted in a slight improvement to stability over a period 
of 120 hours at 27°C, however the same amount of fresh medium resulted in no change to stability. 
The addition of 0.1x-1x CLC supplements to the buffer resulted in dramatic decreases to ACAM529 
stability at 27°C, especially in the first 24h. Lastly, Pluronic F68 (PF68) at concentrations below the 
critical micelle concentration (CMC), significantly improved viral titers after 120h, with maximal 
stability achieved at a concentration of 0.1% PF68. 
Lastly, other excipients that have been implicated in enhancing the stability of protein and lipid-based 
products were investigated for ACAM529 stabilization.  An acidic buffer (pH 5) condition caused an 
improved initial infectivity of the virus when titered with the plaque assay, however it had a negative 
impact on long-term stability compared to buffers in the range of pH 6-7. The replacement of 10% 
(w/v) sucrose with 10-30% (w/v) trehalose in the reference buffer did not result in changes to viral 
stability at pH 6-7 at 27°C. Also, the addition of 0.01-0.1 M L-arginine (along with the resulting 
increase in buffer ionic strength with the addition of Cl- ions) and 0.1x-1x non-essential amino acid 
solution (NEAA) did not significantly affect the stability of ACAM529. 
This work showed that it was possible to improve the stability of ACAM529 in the current liquid 
buffer. The highest level of stability was achieved with the addition of 1% FBS. The addition of 0.05 
g/L rHSA or 0.1% PF68 also significantly improved the virus stability and these compounds have the 
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The prevalence of herpes simplex virus type 2 (HSV-2) globally is a major cause for concern. It is a 
highly infectious and contagious sexually transmitted disease affecting over 400 million people 
worldwide as of 2012 1 and there is currently no cure for this life-long affliction. It is the leading 
cause for genital ulcerative disease, resulting in fever, body aches, swollen lymph nodes and, most 
notably, painful recurring lesions on the skin and mucosal layers surrounding the genitalia 2. In 
addition to the physical ailments caused by the virus, the psychological effects are also significant as 
the social stigma associated with the disease can cause distress and ultimately decrease quality of life. 
Though it is rarely a life-threatening disease in adulthood, transmission of the virus to neonates 
during birth runs the risk of causing neurological disease and it is frequently lethal 3. Furthermore, 
active shedding of HSV-2 significantly increases the susceptibility to infection by human 
immunodeficiency virus (HIV), leading to the life-threatening condition, acquired immunodeficiency 
syndrome (AIDS) 4,5. It is clear from its high prevalence and numerous risks that an effective and 
affordable vaccine against HSV-2 is necessary. 
There have been numerous attempts at developing an efficacious vaccine with some currently 
undergoing clinical trials 6,7. The HSV-2 virus is an enveloped double-stranded DNA virus and there 
are many strategies for vaccine development. Subunit vaccines containing the glycoproteins naturally 
embedded in the viral envelope, such as GlaxoSmithKline’s gD-2 8, and Chiron’s gD-2 and gB-2 9 
containing vaccine candidates, have thus far failed to illicit an effective broad immune response. 
DNA and single-replication vaccines have shown more promise as they were found to be more 
immunogenic 7. One promising candidate vaccine is ACAM529, a live replication-deficient HSV-2 
virus with two DNA replication associated genes, namely UL5 and UL29, deleted from its genome. Its 
effective immunogenicity relies on its ability to establish an acute infection in host cells and express 
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several potentially antigenic viral proteins that can be displayed by the infected cell to elicit an 
immune response 10. To maintain the safety of the vaccine, the virus fails to amplify whole viral 
particles and lacks the ability to establish a more permanent latent infection 11. ACAM529 was first 
developed by Dr. David Knipe’s research group at Harvard Medical School and is currently licensed 
by Sanofi Pasteur. It is produced in a recombinant Vero cell line containing a copy of the deleted 
genes missing in ACAM529 to complement the virus genome and its amplification. The viral product 
is then harvested and purified through various steps. The final purified product is then frozen before 
undergoing other downstream processing such as formulation and lyophilization 12.  
The production and development processes expose ACAM529 to various conditions that are 
potentially harmful to the virus. ACAM529 contains a lipid envelope with glycoprotein spikes that 
are essential to its efficacy but these features also make the virus highly susceptible to inactivation. 
Enveloped viruses are notoriously less stable than their non-enveloped virus counterparts 13. The 
glycoproteins are essential for viral attachment and entry 14 and thus it is crucial that the structure and 
function are retained by optimizing the surrounding environment. By extension, the integrity of the 
lipid membrane in which they are embedded must also be protected. However, the lipid membrane is 
especially vulnerable to changes in pH, temperature, osmotic pressures, ionic strength, and 
mechanical stresses such as shear forces 15. ACAM529 is highly likely to be exposed to these factors 
during the manufacturing process. It is of great interest to study ACAM529 and devise methods to 
improve its stability. 
1.1 Purpose 
The purpose of this work is to develop a buffer for the stabilization of ACAM529 to prevent 
significant losses in viral titer during the purification process. The improved stability of ACAM529 




By studying the differences in the stability profiles of various lots of ACAM529 that have been 
produced using different processes, a more directed approach towards stabilizing the virus is possible. 
For instance, compounds and solutions used during the cell culture for ACAM529 production have 
the potential to reveal novel excipients that stabilize the virus. Furthermore, it is hypothesized that 
strategies used in formulations for other lipid- and protein-based products could be applied to 
ACAM529 as it is an enveloped virus with glycoprotein spikes. 
1.3 Objectives 
The objectives of this research are as follows: 
1. Characterize different lots of purified ACAM529 to establish a baseline from which 
improvements to the buffer can be made. 
2. Screen for potential stabilizing agents in complex and defined solutions used for virus 
production in cell culture. 
3. Identify and screen other stabilizers of interest that have been used for lipid- and protein-
based products for the effective stabilization of ACAM529. 
1.4 Outline 
This thesis first presents a brief background about the biology of HSV-2, the development and 
production of the ACAM529 vaccine candidate, and a literature review on excipients used for protein 
and lipid-based biological stability. The next chapter, Chapter 3, summarizes the general materials 
and methods used throughout this work. Next, the following three chapters detail the findings of this 
research. Chapter 4 explores the characteristics of different lots of ACAM529, Chapter 5 investigates 
the stabilizing effects of various solutions and compounds used in cell culture, and Chapter 6 screens 
other commonly used excipients for their stabilization properties for ACAM529. A discussion about 
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the findings of this work is presented in Chapter 7 and concluding remarks about the research in 






2.1 Herpes simplex virus type 2 
The highly infectious herpes simplex virus type 2 (HSV-2) is the major cause of genital ulcerative 
disease and according to the World Health Organization, an estimated 417 million people worldwide 
between the ages of 15 and 49 were affected in 2012 1. It persists to varying degrees in different 
populations, with the highest prevalence being in Africa (31.5% of the population in 2012), followed 
by the Americas (14.4%). The virus is capable of establishing latency in sensory neurons and 
activation leads to viral replication in epithelial cells. Infected individuals who are actively producing 
and shedding the virus easily transmit it through sexual contact and the established infection is life-
long. Its high resilience in the host system can be attributed to its ability to establish a latent infection 
in host neuronal cells, allowing it to effectively evade the immune system 16. The disease rarely 
causes life-threatening symptoms, however the more problematic aspect of HSV-2 infection is the 
increased susceptibility to HIV (human immunodeficiency virus) infection. HSV-2 infection sites 
actively recruit CD4+ cells to the surface, the preferred target of HIV, increasing the chance for an 
HIV infection. There is currently no cure for HSV-2 related disease but the disease and associated 
risks warrants the great need for an effective vaccine. 
2.1.1 HSV structure 
HSV is an enveloped double stranded DNA virus belonging to the herpesviridae family of viruses, all 
of which establish latency in their host. HSV-2 is further categorized into the alphaherpesvirinae 
subfamily, which also includes the closely related cold sore-causing virus, HSV-1. These viruses are 
so characterized due to their specificity for sensory neurons for latent infections, where HSV-1 targets 
the trigeminal ganglion (part of a cranial nerve), and HSV-2 the dorsal root ganglion (part of a spinal 
nerve). The extent to which HSV-1 has been studied in the literature far surpasses that of HSV-2, so 
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this literature review also describes aspects of HSV-1, relying on the high instance of homology 
between the two serotypes 2.  
The HSV viral particle has four major components: the DNA core, the protein capsid, the tegument 
layer, and the lipid envelope embedded with glycoprotein spikes (Figure 2.1A). 
2.1.1.1 DNA core 
In electron spectroscopic techniques, the HSV genome appears as an electron-dense region in the core 
of the virus particle. The approximately155 kilobase pair (kbp) HSV-2 DNA genome is linear and 
double stranded. It is arranged as two regions of unique sequences denoted long (UL) and short (US) 
regions, which are flanked by regions of inverted repeat sequences (Figure 2.1B). Gene products have 
been mapped to both the unique sequences and the inverted repeats. The full transcriptome and 
proteome of HSV has yet to be characterized in its entirety but the function of numerous gene 
products have been identified 2. 
2.1.1.2 Viral capsid 
The DNA is surrounded by an approximately 100 nm rigid icosahedral protein capsid made up of 12 
pentamers and 150 hexamers arranged in a T=16 pattern. The capsid is generally quite robust, 
requiring SDS and heat for denaturation 17, and it is composed of viral protein 26 (VP26) (encoded by 
UL35), VP23 (UL18), VP19C (UL38), and the major capsid protein VP5 (UL19)2. It was found to be 
mostly uninfectious without the presence of the viral envelope 18 however, infectivity could be 
rescued by re-encapsulation with synthetic lipid envelopes 19. Without the lipid envelope, the viral 









Figure 2.1 HSV virion and genome structure  
A. Structure of a HSV virion. B. Schematic of the arrangement of the linear HSV DNA genome. 
Long and short unique sequences (UL and US, respectively) are shown as thin lines. The terminal 
repeat and inverted repeat sequences flanking the UL region (TRL and IRL, respectively), and flanking 
the US region (TRS and IRS, respectively) are shown as white boxes. The origins of replication are 




Electron microscopic imaging revealed a distinct asymmetrical positioning of the capsid within viral 
particles and this is due to the complex network of proteins constituting the tegument layer 20. The 
tegument is seen to cause a distinct polarity in viral particles in that the viral capsid is localized at one 
pole, whereas tegument proteins dominate the opposite pole. Later studies observed that cell-
associated viral particles had a more symmetrical arrangement of the capsid within the tegument 
layer, which then becomes altered upon release into the extracellular environment 21. Over time, the 
tegument of the released viral particle also becomes increasingly resistant to dissociation from the 
capsid with TritonX-100 treatment 21,22. It is composed of over 18 viral proteins with functions related 
to capsid transport to the nucleus and viral DNA release (e.g. VP1/2 encoded by UL36), viral 
transcriptional regulation (e.g. infectious cell protein 0 (ICP0), ICP4), and host gene regulation and 
immune evasion (e.g. ICP34.5, VHS (virion host shut-off encoded by UL41)), among others 23. The 
tegument has been further classified as an inner tegument layer acquired in the host cytoplasm with a 
diameter of approximately 120 nm, and an outer tegument layer acquired upon envelopment with a 
diameter of up to 160 nm 24. 
2.1.1.4 Lipid envelope 
The virus is enveloped in a lipid bilayer membrane acquired from the host cell. To generate the viral 
envelope, HSV was found to affect cellular lipid metabolism upon infection. A relatively early study 
in arterial smooth muscle cells found infection with HSV-1 promoted the accumulation of 
intracellular cholesterol 25. A later study in Vero cells found that HSV-1 infection resulted in 
increases to cell size and the Golgi network, to ultimately increase the overall amount of lipid 
membranes throughout the cell to support viral envelopment 26.  
The composition of the envelope can vary depending on the cell type 27 and there are several theories 
regarding the origin of the membrane, i.e. whether it is from the nuclear, Golgi, or cellular membrane. 
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The more widely accepted theory suggests that viral particles acquire Golgi-derived membranes 28 
and there was evidence of similarity between the HSV envelope and the Golgi membranes. The 
envelope of HSV-1 produced in Vero cells was found to contain the phospholipids 
phosphatidylcholine (51.2%), phosphatidylethanolamine (29.8%), phosphatidylinositol (11.3%), 
phosphatidylserine (4.6%), sphingomyelin (3.1%), which were similar to concentrations in the Golgi 
membrane 29.  
2.1.1.5 Glycoprotein spikes 
The HSV envelope is embedded with several types of viral proteins that play a major role in viral 
pathogenicity. They are involved in viral entry mechanisms, cell-to-cell spread of virus 14, egress 
pathways, and mediation of cell-cell fusion 2,30. The composition of the envelope proteins were 
observed to be independent of the host when two unrelated cell lines (baby hamster kidney (BHK) 
cells and HeLa cells) were used to produce HSV-1 31. There are approximately 11 glycoproteins on 
the viral envelope, including gB, gC, gD, gE, gG, gH, gI, gK, gL, and gM, as well as some non-
glycosylated proteins such as UL20 and US9 2,30,31. Electron microscopy of HSV particles shows the 
glycoproteins as protruding spikes that vary in their dispersion around the viral particle 20. 
Glycoprotein B appears as T-shaped and clusters (approximately14 nm), whereas gC (approximately 
24 nm) is more widely dispersed. The most abundant glycoprotein, gD (8-10 nm) also clusters but in 
a distinct irregular pattern 32. 
2.1.2 Virus replication cycle 
Primary infection by HSV typically occurs at the mucosal layer but it has been shown to infect a wide 
variety of cell types 32. The virus replication cycle in host cells typically takes 18-24h and it is quite 
complex. It involves several stages: attachment, entry, amplification, assembly, and egress.  
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2.1.2.1 Attachment and entry 
The first step in the virus replication cycle of HSV is attachment to the host cell membrane and this is 
accomplished by the interaction of HSV glycoproteins to several potential receptors. Glycoprotein B 
(or gC to a lesser extent) binds to glycosaminoglycan chains (GAGs), preferably heparan sulfate, on 
the host cell membrane to anchor the particle to the surface and bring gD into closer proximity to its 
specific receptors 33. The binding of gB to GAGs is not essential to infection but it greatly enhances 
the infectivity of the virus 34.  
The HSV-specific receptors found naturally on the host cell membrane include the herpesvirus entry 
mediator (HVEM), nectins, and 3-O-sulfated heparin (3-OS HS). The receptors recognized by HSV-2 
gD are HVEM, nectin-1, and nectin-2. In comparison, HSV-1 gD binds HVEM, nectin-1, and 3-OS 
HS, but does not typically bind nectin-2 35. HVEM is part of the tumour necrosis factor receptor 
superfamily and is the principal receptor. It is found on many cell types including epithelial and more 
commonly, on T lymphocytes (i.e. T cells). Nectin-1 and -2 are cell adhesion molecules, part of the 
immunoglobulin superfamily, and they are found in a variety of cell types including epithelial cells, 
fibroblasts, and neuronal cells 34. 
The interaction between gD and its receptors induces a conformational change in gD that activates the 
gH-gL heterodimer complex. This, in turn, activates gB into its fusogenic form which initiates fusion 
of the viral and cellular membranes and release of the viral capsid and tegument into the cytoplasm 36.  
Whether the fusion of the lipid membranes occurs at the plasma membrane or in cellular endosomes 
is cell-type dependent. Entry of Vero (African green monkey kidney) and HEp-2 (human epithelial 
type 2) cells by HSV predominately occurs at the plasma membrane. However in CHO (Chinese 
hamster ovary) and HeLa cells, HSV is taken up by the cells through endocytosis and membrane 
fusion occurs in both a pH-dependent or pH-independent manner 37. Regardless of the manner in 
which the virus enters the cells, the same glycoproteins are involved 2.  
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Upon release of the tegument and capsid into the cytoplasm of the cell, the outer tegument proteins 
are shed and the capsid is transported to the nucleus along microtubules via the host cell motor 
protein, dynein 23. Inner tegument proteins (e.g. pUL36) are involved in the targeting of the viral 
particle to a nuclear pore complex where the capsid is docked and DNA is released through the pore 
into the host cell nucleus 38,39. 
2.1.2.2 Amplification 
The primary objective of the virus is self-amplification. This is initiated in the host nucleus and uses 
both viral and cellular factors. Once the viral DNA has entered the nucleus, a variety of viral 
products, such as proteins, noncoding RNAs, and micro RNAs, are produced in a complex and 
coordinated manner 2. The immediate-early or α genes are those expressed first and in the absence of 
viral protein synthesis. The highest rates of synthesis are detected between 2-4 hours. The α genes 
autoregulate their expression, as well as induce the expression of early or β genes, which reach peak 
synthesis rates between 6-12 hours after infection. Both α and β genes then induce the expression of 
late or γ genes. The expression of γ genes, unlike α and β genes, is affected by DNA synthesis to 
differing degrees 2. For example, the expression of true late genes (γ2 genes), such as UL38 (codes 
capsid protein VP19C) and UL44 (codes gC), requires DNA synthesis. Late in the infection cycle, the 
γ gene products repress the expression of α and ß genes.  
In addition to amplifying viral proteins, the genome must also be amplified. Viral DNA replication 
occurs between 3-15 hours after infection within replication compartments in the nucleus and 
involves seven β genes 2. First, the origin-binding protein (coded by UL9) binds the origin of 
replication sites in the genome, oriL or oriS (Figure 2.1B), and begins to unwind the double stranded 
DNA. ICP8, a single-stranded DNA binding protein (coded by UL29), is recruited to stabilize the 
unwound DNA. Both proteins signal the recruitment of the helicase-primase complex (composed of 
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UL5, UL8 and UL52) and the viral polymerase complex (composed of UL30 and UL42) to initiate DNA 
synthesis 2. 
2.1.2.3 Assembly and egress 
Assembly of the HSV particles is initiated within the replication compartments with capsid assembly. 
Newly synthesized and partially assembled capsid proteins localize into the nucleus from the 
cytoplasm, where they are fully assembled. Once the capsid is formed, one copy of the linearized 
double stranded viral DNA is packaged into each capsid through a portal complex 40 and the resulting 
particle is designated as a mature nucleocapsid. 
Viral egress is the next step in the infection cycle and it requires the acquisition of the tegument layer 
and envelope around each mature nucleocapsid. As mentioned in section 2.1.1.4, it is still widely 
contested where the virus acquires its lipid envelope, however the more accepted mechanism is the 
envelopment-de-envelopment-re-envelopment process. The first envelopment occurs at the inner 
nuclear membrane. Mature nucleocapsids bind to inner tegument proteins; VP1/2, pUL37, VHS, 
VP22 and VP16, and these interact with the inner tails of viral glycoproteins embedded in the inner 
nuclear membrane 23. A primary envelope is acquired as the virion buds into the perinuclear space 
and this process requires the viral proteins pUL31 and pUL34, which constitute the nuclear egress 
complex (NEC).  
The enveloped primary virion is subsequently de-enveloped at the outer nuclear membrane through 
membrane fusion, mediated by gB, gH-gL heterodimer complex, and pUS3 41. The nucleocapsid is 
released into the cytoplasm where it acquires its inner tegument proteins, including pUS3, pUL36, and 
pUL37. Tegumentation proceeds as the virion is transported to the trans-Golgi network (TGN) where 
it acquires the outer tegument 28. Tegument protein pUL48 interacts with several outer tegument 
proteins, such as pUL41, pUL46, pUL47, and pUL49 42, as well as with the cytoplasmic regions of 
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glycoproteins gB, gD, and gH, which are embedded in Golgi membranes 43. The outer tegument is 
further anchored to the membrane by pUL11, pUL16, and pUL21 23, where pUL11 was shown to 
interact with the envelope glycoproteins gD and gE in HSV-1 44 and envelope protein pUL56 in HSV-
2 45. The TGN is the site of secondary envelopment as the virus buds into the vesicles. The final stage 
of egress is the release of the enveloped virus particles and this occurs through cellular exocytotic 
pathways 23.  
Newly released viruses tend to associate with cellular membranes and thus, cell-to-cell spread of the 
virus relies heavily on interactions between adjacent cells 46. Glycoproteins gE and gI, which localize 
to the lateral surfaces of cells where junctions are present 47, play an essential role in cell-to-cell 
spread 14. Deletion of either glycoprotein reduced plaque sizes in monolayers of human fibroblasts 
however in Vero cells, the reduction in plaque size was less apparent 48. 
2.2 ACAM529 vaccine candidate 
2.2.1 Development of dl5-29 
The double deletion replication-deficient HSV-2 mutant, ACAM529, was first developed by Dr. 
David Knipe’s research group at Harvard Medical School. The immunogenic success of a live HSV-1 
mutant with a deletion in gene UL29 in protecting mice from HSV-1 associated disease 49,50 drove the 
research towards creating a similar mutant in HSV-2.  The HSV-1 UL29 deletion mutant was able to 
infect permissive cells and express alpha and beta genes, but was unable to produce progeny virus as 
ICP8, the UL29 gene product, plays a key role in gene expression and genome synthesis. ICP8 is the 
major viral DNA-binding protein and it mediates the unwinding of the double stranded DNA and 
stabilizes the single strands. It is also involved in the transcriptional regulation of gamma genes 2. 




It was observed that de novo synthesis of viral proteins was a key factor towards a strong 
immunogenic response in mice. The HSV-1 UL29 deletion mutant had stronger immunogenic 
properties than an ICP4 deletion mutant, which could only express some alpha genes. Furthermore, a 
UV-inactivated HSV-1 virus was not an effective vaccine against an HSV-1 challenge 49. The UL29 
deletion in HSV-1 and -2 behaves similarly 10. In HSV-2 UL29 mutants (dl29), viral DNA replication 
was not detected but significant expression of some late genes (ICP5, ICP15, ICP25, gB, gD) was 
detected. gB and gD, important targets for anti-HSV immunity, were detected at only slightly lower 
levels than wildtype virus. 
To reduce the probability that the virus could revert back to a wild type virus, a second gene, UL5 was 
deleted in addition to UL29 in HSV-2 (dl5-29) 51. The UL5 gene product is part of the helicase-
primase complex involved in viral DNA synthesis 2. Similar to the dl29 virus, the dl5-29 virus only 
replicated in complementary Vero cells engineered to express the missing genes, in this case UL5 and 
UL29 51. The dl5-29 virus showed similar expression of viral genes as the wild type HSV-2 strain (186 
syn +-1) in both monkey (Vero) and human (HEL299 or human embryonic lung fibroblast, and MRC-
5 or medical research council strain 5 human fetal lung fibroblast) cell lines but at lower levels for 
some late proteins such as gB, ICP5, and ICP25 51. In mice infected with dl5-29, vaginal shedding 
was significantly reduced and the virus notably failed to establish a latent infection in mouse neuronal 
cells 11. 
2.2.2 Virus manufacturing 
Virus manufacturing involves several stages (Figure 2.2). Essentially, virus is produced during 
upstream processes, concentration and purification is achieved during downstream processes, then the 










2.2.2.1 Upstream processes 
Virus vaccine production requires an animal cell line (or insect cell line for some systems) for 
amplification. The upstream process generally involves culturing the cells to the appropriate density, 
inducing virus production in the cells, and after sufficient time, harvesting the culture to obtain 
maximum virus yield.  
The cell line may either be anchorage-dependent, where a surface is required for proliferation, or it 
may grow in suspension. Most animal cell lines are anchorage-dependent, however they are not ideal 
for scale-up and are more labour-intensive. Large surface areas are required for culturing higher cell 
densities and a detachment step is necessary for passaging 52. Some cell lines, especially tumour-
derived cell lines, can be adapted to grow in suspension. Suspension cell lines are more ideal for 
scale-up since they can be passaged by dilution and can be grown to higher density in solution. Shear 
forces are one concern however, due to the mixing required for suspension cultures 52. 
Cells are grown to the appropriate density by optimizing parameters such as pH, temperature, 
dissolved oxygen, pressure, and nutrient supply. It is more advantageous to use chemically defined 
culture media and supplements as not only do they reduce batch-to-batch variability, but the risk of 
containing harmful pathogens is reduced, unlike with animal-derived serums 13. This is especially a 
concern for products intended for clinical applications.  
Once the desired cell density has been achieved, virus production is induced. The cell line may either 
be stable, where it is engineered to contain the necessary genetic material to produce virus, or it may 
produce virus transiently. For transient cell lines, induction by for example providing the necessary 
DNA plasmids, or infecting with the virus, is necessary for production 52. The multiplicity of infection 
(MOI) is the ratio of virus particles to cells and ideally, the lowest MOI for optimal virus production 
is used to induce production. The culturing parameters may also be altered during production for 
optimal output and this is specific for each type of virus product. After incubation, the culture is 
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harvested at the optimal time for maximal product yield and the virus undergoes downstream 
processing. 
2.2.2.2 Downstream processes 
Upon harvest, the next step in manufacturing is recovery, where the virus is separated from cell debris 
and other solid contaminants. This process is simplest if the virus is secreted or buds into the 
extracellular space. The virus can be harvested by sedimentation of the cells using centrifugation and 
collecting the supernatant. This is the gold standard for clarification of the solution and is optimized 
for maximal removal of cells with minimal cell lysis 53. If the virus tends to adhere to the cell surface, 
which is the case with HSV, an eluting agent can be used. Dextran sulfate is an analog of heparin, an 
HSV receptor used for cell attachment prior to infection. ACAM529 recovery was increased when 
dextran sulfate was used in the harvesting media 12.  
If the virus is intracellular, it can be liberated by subjecting the cells to lysis-inducing stresses such as 
high pressure (homogenizers), osmotic shock, or sonication. In addition to releasing the virus into 
solution, cell disruption also releases other intracellular impurities, such as cellular DNA and 
proteases, which must be removed in subsequent steps and further complicates the purification 
process 53. Removal of host cell DNA is often achieved using enzymes. Benzonase digests DNA into 
smaller molecules so that it can be removed more readily and in turn reduce the viscosity of the 
solution. Benzonase treatment prior to filtration reduced membrane fouling and improved the step 
yield of ACAM529 12. Microfiltration is then used to remove any large or solid contaminants. 
The next step in downstream processing is to reduce the working volume and remove dissolved 
impurities from the clarified lysate. Ultrafiltration uses a porous membrane to allow water and small 
dissolved particles to pass through (permeate) while retaining larger-molecular weight particles, such 
as the virus (retentate). Concentration of the virus can therefore be achieved using ultrafiltration. For 
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large-scale processes, ultrafiltration using tangential flow filtration (TFF) is commonly used 54. 
Unlike with conventional or dead-end filtration, where the flow of the solution is perpendicular to the 
porous membrane, in TFF the flow of the solution is parallel to the membrane. This reduces 
membrane fouling because the parallel flow is able to effectively wash the membrane of 
accumulating particles. However there are increased shear forces due to the high flow rates required 
54.  
Once the working volume has been reduced, a buffer exchange step is often subsequently performed 
using diafiltration. The new buffer is added to the inlet of the TFF step to wash and displace culture 
media and small molecule impurities from the virus solution. This buffer is typically optimized for 
maximal product stability while also being tailored for specific subsequent purification steps 54. For 
ACAM529, a typical stabilization buffer contains 10% (w/v) sucrose, 10 mM L-histidine, 50 mM 
potassium glutamate, 160 mM NaCl, pH 7 12. 
The final stage in downstream processing is purification and polishing. The virus is separated from 
impurities based on specific physical properties. Column chromatography can be used to separate 
based on ionic strength (ion-exchange chromatography), hydrophobicity (hydrophobic interaction 
chromatography), or size (size-exclusion chromatography) 54. Ion exchange and hydrophobic 
interaction chromatography are absorptive chromatography techniques, which contain beads that are 
engineered to interact with or bind to chemicals. They are then gradually eluted from the column and 
the fraction containing the virus is collected. Size-exclusion chromatography contains a porous 
stationary phase that allows small molecules to enter and this effectively slows the rate at which they 
pass through the column. Larger particles elute faster because they are not able to enter the pores. 
Chromatography techniques require optimization to ensure the matrix adequately captures the virus 
with minimal inactivation, while reducing the adsorption of contaminants. The subsequent elution of 
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the virus from the column also needs to be optimized for maximal recovery of active virus 53. Once 
the product is adequately purified, it is then prepared for final formulation and packaging. 
2.3 Components of stabilization solutions 
Biologics that contain lipid membranes, such as ACAM529, are particularly more thermolabile than 
their protein counterparts. The membrane is sensitive to changes in the environment such as osmotic 
pressures, ionic strength, surfactant concentrations, shear stresses, and temperature 13. They can also 
be easily damaged by ice crystal formation encountered during freezing and can be dissociated using 
detergents 55. ACAM529 also contains several glycoproteins embedded in the lipid membrane whose 
function is essential to the vaccines antigenicity. To maintain their structure and function, proteins 
require specific pH, ionic strength, and temperature conditions 56. The key components of a 
stabilization solution are an appropriate buffering agent to maintain the ideal pH, and various 
excipients that help protect the biological material from unwanted chemical and physical reactions, 
while also maintaining the correct osmolarity and ionic strength. 
The following sections explore various components of liquid stabilization buffers for biological 
products with lipid membranes, as well as protein-based biologics. Literature on liquid formulation of 
enveloped vaccines is lacking, as lyophilization is the method of choice for storage.  
2.3.1 Buffer pH 
The pH of the solution has been regarded as an important attribute to control, especially for protein 
and peptide products, as it has an effect on both chemical and physical degradation pathways. For 
example, certain pH conditions can promote unwanted acid-base catalyzed reactions, deamidation of 
asparagine and glutamine residues, and charge variations that cause structural unfolding 57. These 
reactions can ultimately lead to the loss of vaccine antigenicity. 
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Buffering agents commonly used include citrate, acetate, phosphate, Tris, amino acids such as 
histidine and glycine and buffer in the range of 3-10. Careful selection of buffering agents is 
necessary as the buffer ions may interact with the protein in both stabilizing and destabilizing 
pathways. Some buffers such as phosphate-buffered solutions are particularly prone to temperature 
induced pH shifts 58 and others are susceptible to degradation upon exposure to light or trace metals 
such as citrate 56. Tris buffer was found to stabilize retrovirus better than phosphate buffered saline 
due to its superior pH stability, especially at freezing temperatures in both liquid and freeze-dried 
form 59. Phosphate buffers are particularly ill suited for freezing because the base (Na2HPO4) 
crystallizes faster than the acid (NaH2PO4) causing pH drops. Buffers which do not crystallize but 
form amorphous systems have less changes in pH 57. 
The buffering agent in the ACAM529 reference buffer is 10 mM histidine, pH 7 12, with pKa = 6.04 
for the imidazole side chain. In the range of pH 5.5-7, histidine was found to have optimal buffering 
capacity (0.47-0.49 micro equivalents of acid or base required to change the pH of the system by one 
unit per micromole of buffering agent (µEq/µmol)) 60. At pH 7-8, the buffering capacity was 
significantly reduced to 0.16 µEq/µmol. 
2.3.2 Buffer ionic strength and osmotic pressure 
The ionic strength of a solution is an important factor when considering the stability of enveloped 
products and care should be taken to control this. It was shown to be important for optimizing the 
charge interactions between phospholipid moieties in lipid membranes. Monovalent and divalent 
cations increase the strength of the membranes of E. coli and synthetic liposomes with increasing 
ionic concentration 61. Ionic strength also has an effect on buffering capacity. Self-buffering 
monoclonal antibody (mAb) solutions had a 25-35% difference in buffering capacity between pH 8.0-
5.0 when NaCl concentrations were increased from 10 mM to 160 mM. Histidine, however, was 
minimally affected by this ionic strength change, with only 15-10% difference 60. 
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Ionic strength also has a direct effect on the osmotic pressure of a solution and can thus cause 
shrinkage or swelling. An enveloped influenza vaccine experienced shrinkage and membrane 
perturbations in a hyperosmotic solution but when the viscosity of the solution was increased with 
methylcellulose, the osmotic stress effects were minimized 62. Significant inactivation of HSV-2 was 
seen with rapid drops in osmotic pressure (from dilution) but not with a gradual drop 63. Conversely, 
high osmotic pressures can effect the environment within the capsid of enveloped virus. The ability of 
HSV-1 to eject its viral DNA contents from capsids was directly hindered by an increasing 
concentration of polyethylene glycol (PEG) that increased the external osmotic pressure 38.  
2.3.3 Stabilizers 
Many pathways for inactivation and product loss can be mediated through stabilizers. Proteins and 
lipid-based biologics are susceptible to numerous degradation pathways and remedying this is a more 
complex challenge. Product loss may occur from unfavourable chemical reactions, aggregation, or 
from adhesion to container surfaces or air-liquid interphases caused by hydrophilic or electrostatic 
interactions 64. This can have a profound effect on product yield, as it can lead to irreversible 
denaturation or reduce the bioavailability of the product.  
2.3.3.1 Preferential exclusion 
A broad range of excipients has been identified with the ability to stabilize proteins and this suggests 
that specific binding effects between the protein and excipient are not involved. The preferential 
exclusion theory postulates that excipients are excluded from the protein and this promotes a stronger 
interaction between the protein and solvent to produce a hydration shell 65. This state favours the 
native structure of the protein since unfolded proteins would have more surface area and thus a higher 
chemical potential than the native state. The interaction and binding between excipients and proteins, 
such as that with arginine or lysine and RNase A, decreases the transition temperature and thermal 
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stability of the protein compared to when excipients are excluded, such as with trehalose 66. However, 
with increased temperatures, trehalose was also found to bind to the native state of RNase A but this 
binding was observed to be stabilizing and protected the enzyme from thermal inactivation 67. 
2.3.3.2 Sugars and other carbohydrates 
Sugars and other carbohydrates are widely used stabilizers for their effect on preferential exclusion in 
liquid solution and also because they are effective cryoprotectants. Disaccharides remain amorphous 
during freeze-drying, where they are thought to form a glass around the product 55,68. An amorphous 
matrix is preferred over crystalline due to the increased risk of damage to lipid membranes from 
crystal formation. They are also thought to protect products from damage induced by lyophilization 
by taking the place of water in hydrogen bonds to polar surfaces on proteins and with the carbonyl 
groups of lipid membranes, allowing them to maintain their native structure 69,70.  
Several disaccharides, such as lactose, maltose and cellobiose, and all monosaccharides are reducing 
sugars and they are typically avoided for formulation. Reducing sugars tautomerize to an open chain 
form where the aldehyde group undergoes a Maillard reaction with free amino groups on proteins, 
altering charge, conformation, and degradation rates 71. The Maillard reaction between glucose and 
amino side chains of the protein therapeutic, human relaxin, was found to be the major cause of 
instability. However, trehalose and mannitol prevented this reaction 72. 
Conversely, sucrose and trehalose are non-reducing sugars. The anomeric carbons involved in the 
glycosidic bond prevents the molecule from reverting to the open-chain. However, in acidic 
conditions, sucrose has been shown to hydrolyze into its monomeric constituents, glucose and 
fructose, which are both reducing sugars 73. This becomes relevant during freezing, because uneven 
freezing of the solution may create microenvironments with elevated proton concentrations, thus 
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reducing pH. In nature, sucrose and trehalose act as osmolytes to protect intercellular environments 
from harsh temperatures and low water levels 56. 
Sucrose is widely used in vaccine formulations 13,55,74 and it is present in the stabilization buffer for 
ACAM529. A phosphate buffered sucrose solution improved the stability of several enveloped virus 
after freezing and warmer temperature storage (4°C and 20°C). It was found to be a superior stabilizer 
to sorbitol for cytomegalovirus (CMV), varicella-zoster virus (VZV), respiratory syncytial virus 
(RSV), and HSV-1 75. Another increasingly popular disaccharide used in formulation is trehalose 
55,66,67,69,70,72,76,77 and it has been shown to have superior properties over sucrose. Trehalose has a 
higher viscosity than several sugars, including sucrose, and it has superior stabilization properties for 
numerous proteins. The stabilizing effect on the protein enzymes pyrophosphatase and on glucose 6-
phosphate dehydrogenase using 0.5 M trehalose was similar to that with 1.5 M sucrose 69. The 
superior stabilizing effect of trehalose over sucrose is not universal. It is dependent on the specific 
product to be stabilized, as sucrose-containing solutions have been shown to perform better than or 
similar to trehalose-containing solutions 55. During lyophilization, mannitol and polyethylene glycol 
(PEG) were observed to crystallize and were not able to offer any protection for the recombinant 
human protein Factor XIII. Dextran is able to form an amorphous phase with the protein but this is 
not enough for protection. Trehalose and sucrose are both able to form a glass around the protein and 
form hydrogen bonds with the protein in place of water, which is more protective 78. 
Sugars, sugar alcohols, and other compounds have also been shown to have membrane-stabilizing 
properties. The membrane integrity was deemed to be an essential characteristic for measles virus 
stability 79. The infectivity of a measles viral vaccine was improved with the excipients mannitol, 
myo-inositol, proline, malic acid, or gelatin. Lactose, malic acid, and gelatin-containing formulations 
protected against temperature induced swelling of the virus. Mannitol and malic acid were also shown 
to function as membrane hydration inhibitors and proline decreased the overall change in membrane 
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hydration. Increased membrane hydration increases the polarity and thus reduces the stability of lipid 
membranes 79. In another study, trehalose and glycine were found to reduce membrane hydration 
effects at higher temperatures for an enveloped influenza VLP 77. 
2.3.3.3 Amino acids 
The role of amino acids in solution can by multifold. They are often used as anti-aggregation agents, 
anti-oxidants, and buffering agents as described previously. Aggregation was seen to be a major issue 
with influenza VLPs so glycine and the secondary amine and diol, diethanolamine, were used to 
reduce aggregation. They had a neutral effect on the tertiary structure of the protein spikes, suggesting 
that particle aggregation was prevented by directly interfering with protein-protein interactions 77.  
Arginine has been widely used in protein stabilization solution for its ability to reduce aggregation. 
Chromatography techniques used in mAb production were improved using 1 M arginine. Protein 
aggregation was reduced and elution efficiencies from the chromatography columns were increased 
80. L- and D-arginine have also been used to elute measles virus off the surface of erythrocytes. L-
ornithine, which is similar in structure to arginine except the guanidine group is replaced by an amino 
group, was 75% as efficient at elution as arginine 81. Arginine and lysine also improved the solubility 
of the protein: tissue plasminogen activator 57. The mechanism by which arginine prevents 
aggregation is hypothesized to be due to the three methylene groups which form a hydrophobic 
region. Exposed hydrophobic regions on a protein, such as aromatic side chains, are prone to induce 
aggregation and unfolding. The methylene group in arginine can bind to hydrophobic regions on the 
protein, stabilizing the structure and preventing further unfolding 82,83.  
Oxidation can often be the major cause of the denaturation of protein products, especially those high 
in methionine, cysteine, tryptophan, tyrosine, and histidine 84. Histidine prevents oxidation by free 
radicals. The addition of histidine to a liquid formulation for an adenovirus vaccine, which was shown 
 
 25 
to be susceptible to oxidation, improved its stability during long term storage at 4°C 85. The thermal 
stability of a lipoprotein hepatitis B vaccine was also improved with histidine. They tried several 
ionic excipients but found histidine and lactate to perform best, with succinate and malate having 
little to no effect 86. 
2.3.3.4 Surfactants 
Non-ionic surfactants are commonly used as a stabilizer to prevent protein aggregation. Surfactants 
are amphiphilic compounds that have both a hydrophobic and hydrophilic region. They adsorb to 
interfaces, such as air-liquid, solid-liquid, or liquid-liquid, and stabilize compounds that tend to 
denature or aggregate at these interfaces. When these aggregates go back into solution, it induces 
further aggregation and eventually precipitation 56,57. Polysorbate 20 (or Tween 20) and polysorbate 
80 (or Tween 80) are commonly used to protect proteins from aggregation 56. For example, Tween 20 
significantly reduced recombinant human interferon-γ adhesion to air-liquid interphases 87. Genapol 
PF-10, a block co-polymer of polypropylene oxide (hydrophobic) and polyethylene oxide 
(hydrophilic), has been shown to prevent insulin surface adsorption and ultimately decrease 
aggregation 88.  
Surfactants, though useful as anti-adsorption and anti-aggregation agents, also interact with and 
disrupt membranes. Decreased stability was observed with a lipid envelope-containing hepatitis B 
vaccine when Tween 80 was used 13. They are frequently used for cellular membrane lysis and for 
uncoating of enveloped virus for studies 19, though at higher concentrations. Surfactants assemble into 





2.3.3.4.1 Pluronic F68 
Pluronic F68 is a non-ionic tri-block co-polymer surfactant belonging to the family of Pluronics 
composed of terminal polyethylene oxide (PEO) regions that are hydrophilic and a central 
polypropylene oxide (PPO) region that is hydrophobic. Pluronic F68 specifically has an average 
molar mass of 8400 g/mol and is ~80% polyethylene oxide by mass. On average, one tri-block has a 
total of 152.73 hydrophilic ethylene oxide units and 28.97 hydrophobic propylene oxide units (e.g. 
PEO76-PPO29-PEO76). It is commonly used in large-scale animal cell culture as it has the ability to 
reduce the association of cell membranes with bubbles from sparging, and to protect the membranes 
from hydrodynamic forces such as shear stress 89. The mechanism by which it achieves increased 
membrane stability is either through membrane adsorption or insertion. One study showed that its 
increased hydrophilicity compared to other Pluronics favoured lipid membrane association over 
membrane insertion during short (4h) incubations 90. It is theorized that shorter hydrophobic regions 
restrict membrane insertion but instead favour the lateral coverage of the membrane, which has been 
implicated in sealing membrane defects and protecting against leakage 91. Pluronic F68 has also been 
demonstrated to be taken up by chondrocytes and CHO cells 92, however in this case, it was unclear 
whether the polymer was adsorbed to the surface or inserted into the lipid membranes.  
2.3.3.5 Lipids and cholesterol 
Many enveloped virus contain high levels of cholesterol in their lipid membranes. Cholesterol 
enrichment was necessary for HIV 93 and HSV-194 infectivity. Cholesterol is also used in liposomes 
as they confer an increased stability by protecting the bilayers from mechanical breakage 95. However, 
due to the nonpolar nature of cholesterol, increased levels were shown to decrease the overall surface 
charge and ion-lipid interactions in synthetic membranes 96. This reduction in ion-lipid interaction 
would then decrease the strength of the membrane as mentioned above 61. 
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2.3.3.6 Proteins: albumin 
Proteins, especially gelatin and albumin, have been used extensively as stabilizers. They have proven 
to be fantastic anti-adhesion stabilizers as they can compete with the biological product of interest to 
adsorb to surfaces and reduce the amount of product loss. A disadvantage to these stabilizers, 
however, is that they are often animal derived and gelatin has been reported to cause anaphylactic 
reactions 97,98. Recombinant forms of albumin are therefore gaining more popularity. 
Recombinant human serum albumin (rHSA) is another alternative to albumin. rHSA produced in rice 
was found to be similar in structure and biochemistry as plasma-derived human albumin 99 and it was 
found to protect enveloped virus in liquid formulation 100. During production, viral products are 
generally more stable in the culture media due to the presence of many protective agents required by 
the cells such proteins, lipids, and amino acids. When FBS, was added to liquid solutions of 
gammaretroviral or lentiviral vectors, an improved infectivity and reverse transcription activity was 
observed 100. After studying the specific components of FBS, the researchers found that a recombinant 
human serum albumin (rHSA) was sufficient for gamma retroviral stability and a combination of 
rHSA and lipoproteins for lentiviral stability.  
One of the major roles of albumin, which is predominantly alpha-helical in structure, is to bind and 
transport materials through the circulatory system and it has been well documented to bind various 
types of compounds 101. It has 7-9 fatty acid binding sites, and two drug-binding sites known as 
Sudlow’s site I and II 101,102. Bound ligands can have competitive or allosteric effects on the binding 
of other compounds to albumin and furthermore, it can cause conformational changes in secondary 
structure (reduced alpha helical content) and tertiary structure (domain rotations in relation to each 
other). The ability of albumin to bind drugs often increases the drug solubility and half-life in vivo 103. 
Albumin has also been shown to have antioxidant properties, either by binding radical scavengers, or 
sequestering transition metal ions with pro-oxidant activity 104. 
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2.3.3.6.1 Circular dichroism spectroscopy 
Circular dichroism (CD) spectrometry is a popular technique used for rapid protein structural 
analysis. It relies on the property that asymmetrical molecules absorb left- and right-handed polarized 
light to differing degrees, resulting in an elliptically polarized light, and the ellipticity is highly 
dependent on the chemical environment of the molecule 105,106. Spectra in the far UV region (190-250 
nm) are predominantly due to the peptide bond and it can be used to determine protein secondary 
structure. Alpha-helices display strong negative peaks around 208 nm and 222 nm, and a positive 
peak at 193 nm. Antiparallel beta-pleated sheets show negative peaks at 218 nm and positive peaks at 
195 nm. Disordered or random coils display negative peaks around 195 nm and have very low 
ellipticity above 210 nm 106. Spectra in the near UV region (260-320 nm) are due to aromatic amino 
acid side chains: tryptophan causes peaks between 290-305 nm, tyrosine between 272-282 nm, and 
phenylalanine between 255-270 nm 105. The analysis of near UV spectra of proteins is not 
sophisticated enough to give specific structural insights however it can be extremely useful for 
comparative studies. For example, it is often used to assess the proper folding of recombinant protein 





ACAM529 is a live replication-deficient viral vaccine against the disease caused by HSV-2. The 
efficacy of the vaccine relies on its ability to infect and produce potentially immunogenic viral 
proteins in the host cell. It is therefore essential that the lipid envelope of the virus and embedded 
glycoproteins required for cell entry are protected during the manufacturing process. There are 
numerous types of compounds that can be used as stabilizing excipients for protein and lipid-based 
biological products. Though their mechanisms of stabilization are not fully understood, specific types 
of excipients have been implicated in preventing deactivation events such as particle aggregation, 
surface adsorption, oxidation, and membrane disruption. Formulations are often specific to the 





Materials and Methods 
This chapter describes the approaches used to study ACAM529 stability and provides details on the 
general techniques and materials used in this body of work. 
3.1 Viral vaccine candidate 
The vaccine candidate ACAM529 is a live herpes simplex virus type 2 with two genes, UL5 and 
UL29, deleted from its genome, rendering it replication-deficient in susceptible cells. It was first 
developed by Dr. David Knipe (Harvard Medical School, Boston, MA)11,51 before being acquired by 
Sanofi Pasteur (Toronto, ON) for large scale production. Sanofi Pasteur has supplied several lots of 
frozen purified ACAM529, three of which were used in these studies: Lot A, Lot B, and Lot C.  
3.2 Cell line 
A complementary Vero cell line (African green monkey kidney epithelial cells) with the HSV-2 UL5 
gene and HSV-1 UL29 gene cloned into its genome was used to propagate the virus. The cell line, 
developed by Dr. Knipe 11,51, was provided by Sanofi Pasteur and it was stored frozen in the vapour 
phase of liquid nitrogen in 1 ml aliquots at a concentration of 1x106 cells/ml in culture media 
(Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12) (Corning) supplemented 
with 4 mM L-glutamine (Sigma-Aldrich), and 10% fetal bovine serum (FBS) (HyClone)) with 10% 
dimethyl sulfoxide (DMSO) (Sigma-Aldrich).  
3.2.1 Initiating a cell culture 
To initiate a cell culture, a frozen 1 ml vial was quickly thawed in a 37°C water bath and the DMSO-
containing medium exchanged. The cells were diluted 1/10 in culture media, centrifuged at 800 rpm 
for 5 minutes, decanted, and resuspended in 20 ml fresh culture media. Cells were seeded at a 
concentration of ~1.3x104 cells/cm2 on a 75 cm2 tissue culture treated T-flask (Nunc, Thermo 
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Scientific) and incubated at 37°C with 5% CO2 atmosphere until 80-90% confluency with media 
exchanges every 48-72h. 
3.2.2 Cell passaging 
Passages were performed when culture confluency reached 80-90%. The media was removed and 
cells were washed with Dulbecco’s phosphate buffered saline (DPBS), then dissociated from the T-
flask surface using TrypLE (Gibco) for 10 min at 37°C. The suspended cells were diluted with culture 
media, centrifuged at 800 rpm for 5 min to pellet the cells, and the media was removed then replaced 
with fresh media. Cell viability was determined using the trypan blue exclusion method. A small 
sample of the cells was diluted 1:1 in a 0.5% trypan blue solution (HiMedia) in DPBS and counted 
under a microscope using a hemocytometer. Cells were deemed to be alive if they were able to 
exclude the dye and cells were deemed dead if the dye was able to penetrate the cellular membrane. 
The cells were then diluted using culture media and seeded into fresh T-flasks at a concentration of 
1.1-2.7x104 cells/cm2. 
3.3 Time course assay 
A 5-day time course of virus activity at ambient temperatures was chosen as the key response variable 
for changes in conditions and formulation.  
3.3.1 Buffer preparation and baseline formulation 
A reference buffer typical for ACAM529 purification consisting of 10% (w/v) sucrose (Sigma-
Aldrich), 10 mM L-histidine (Sigma-Aldrich), 50 mM potassium glutamate (Sigma-Aldrich), 160 
mM sodium chloride (Sigma-Aldrich), pH 7 12 was used throughout this work as a baseline control. 
Excipients were either added to the reference buffer or used to replace components, as specified. All 
buffers were prepared fresh for each time course assay. 
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3.3.2 Viral preparation 
Frozen purified virus stock from Sanofi Pasteur was quickly thawed at 37°C and diluted 1/100 (see 
Appendix A) in fresh buffer and incubated at the appropriate temperature in 15 ml Falcon tubes 
(Corning). Tubes were covered in foil to reduce light exposure. To monitor viral stability, a small 
volume was removed for titration via the plaque assay. In most cases, titration was done immediately 
after sampling but for cases where sampling times were more frequent, the volume removed was 
frozen at -80°C for storage and then quickly thawed at 37°C prior to performing the plaque assay (see 
Appendix A). If frozen, in all cases, all samples taken at a specific time point were titered at the same 
time. 
3.3.3 Viral titration: plaque assays 
Viral titers during the time course assays were based on a measure of viral infectivity, an important 
attribute for the efficacy of the ACAM529 vaccine candidate. When HSV-2 infects a monolayer of 
susceptible cells, the infection causes plaques to form in the monolayer. At low virus densities, each 
plaque corresponds to a single virus, and the titer can be established as plaque forming units per ml 
(PFU/ml).  
12-well tissue culture treated plates (VWR) were seeded with complementary Vero cells below 
passage 25 (see Appendix A) at a concentration of 3x105 cells/well and incubated at 37°C with 5% 
CO2 atmosphere for approximately 24 hours. The media was removed and cells were washed with 
DPBS. Serial dilutions of the virus were performed in 96-well plates (VWR) using culture media and 
200 µL of viral dilutions were used to infect each well of the 12-well plate. Negative controls were 
included, where 200 µL of media was used instead of the viral dilution, to assess the quality of the 
cell monolayers. Plates were rocked every 15 min for 1 hour, then 1 mL/well of overlay media 
(DMEM/F12 with 4 mM L-glutamine, 1% (v/v) FBS, 100 Units/mL penicillin, 100 µg/mL 
streptomycin solution (Gibco), and 0.75% (w/v) methyl cellulose (Sigma-Aldrich)) was applied and 
 
 33 
plates were incubated at 37°C with 5% CO2 atmosphere for approximately 45-48 hours to allow for 
plaque formation. After incubation, media was aspirated and cell monolayers were dyed with crystal 
violet solution (12.9% crystal violet, 0.056% ammonium oxalate, 11.2% ethanol, 44% methanol) 
(Sigma-Aldrich) for 30 min, and then washed with deionized water. Plaques in the monolayer were 
counted manually and wells containing 20-220 plaques were used to determine the viral titer in units 
of plaque forming units (PFU) per mL as shown in equation [1]: 
𝑃𝐹𝑈 𝑝𝑒𝑟 𝑚𝑙 =  # !" !"#$%&' × !"#$%"&' !"#$%&
!.! !"
    [1] 
To determine the log loss in titer after 120 hours, the logarithm of the average titer at 120 hours was 
subtracted from the logarithm of the average titer at 0 hours, as shown in equation [2]: 
𝐿𝑜𝑔 𝑙𝑜𝑠𝑠 𝑖𝑛 𝑡𝑖𝑡𝑒𝑟 = 𝑓 𝑥, 𝑦 = log 𝑥 − log (𝑦)    [2] 
where 𝑥 is the average titer at 120 hours and 𝑦 is the average titer at 0 hours. Equation [4] was used to 
determine the propagation of error, 𝑠! (general formula shown in [3]) for the value obtained using 
equation [2]: 








𝑠!!       [3] 








𝑠!!      [4] 
where 𝑥 is the average titer at 120 hours, 𝑠! is the associated standard deviation for 𝑥, 𝑦 is the average 
titer at 0 hours, and 𝑠! is the associated standard deviation for 𝑦. All data manipulation and plot 




Transmission electron microscopy (TEM) was used to visualize the structure of ACAM529. 
Formvar/carbon 200 mesh copper grids (Ted Pella, Inc., Redding, CA) were prepared by applying a 
0.01% bovine serum albumin (BSA) (Sigma-Aldrich) solution for 30s and then removing the excess 
liquid. Virus sample was diluted 1/100 in 10 mM HEPES (BDH Chemicals) buffer, pH 6.6 then 
applied to the grid for 1 min. Excess liquid was then drained and the virus was fixed with 2% 
formaldehyde (Sigma-Aldrich) for 5 min. The grids were stained with 1% phosphotungstic acid 
(PTA) for 45s, drained, and left to dry overnight at 2-4°C. Samples were examined on a Philips 
CM10 transmission electron microscope at 25 000x to 60 000x magnification. 
3.5 SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate and 
visualize proteins in the purified viral product. Samples were diluted 1:1 in 2x SDS sample buffer 
(125 mM Tris-HCl (Bio-Rad) (pH 6.8), 4% (w/v) SDS (Sigma-Aldrich), 20% (v/v) glycerol (Bio 
Basic Canada), 5% (v/v) β-mercaptoethanol (Sigma-Aldrich), 0.2% (w/v) bromophenol blue (Sigma-
Aldrich)) and incubated in a boiling water bath for 7 min before loading into 1 mm-thickness SDS-
PAGE gels (12% acrylamide resolving gel with a 4% acrylamide stacking gel). PageRuler Unstained 
Protein Ladder (Thermo Scientific) and PageRuler Plus Prestained Protein Ladder (Thermo 
Scientific) were used to estimate protein size and either recombinant human serum albumin (rHSA) 
(Cellastim, Invitria) or BSA was used as a concentration reference standard. Gels were run at 175 V 
for approximately 1h in running buffer (25 mM Tris base (Bio-Rad), 190 mM glycine (Sigma-
Aldrich), 0.1% (w/v) SDS, pH 8.3). Protein was visualized by staining the gels for 1.5h in Coomassie 
solution (0.05% (w/v) Coomassie R-250 (Bio-Rad), 10% (v/v) glacial acetic acid (Sigma-Aldrich), 
40% (v/v) ethanol (Sigma-Aldrich)), and then destaining overnight in destain solution (10% (v/v) 
glacial acetic acid, 40% (v/v) ethanol). 
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3.6 CD spectrometry 
Circular dichroism (CD) spectrometry was used to detect potential changes to albumin tertiary and 
secondary structure caused by thermal stresses or the addition of excipients. CD spectra were 
obtained on a Jasco J-715 CD spectrometer with the accompanying Spectra Manager software. Scans 
were done at room temperature in quartz SUPRASIL cuvettes (Hellma Analytics, Mullheim, 
Germany) with 0.1 cm path length for the far UV region (250 nm – 180 nm). Samples containing 
albumin were diluted with the appropriate buffer immediately before loading into the cuvette to a 
concentration of 0.5 g/L. The response time used was 0.125 s with a data pitch of 0.5 nm and a scan 
speed of 200 nm/min. A total of 25 accumulations were acquired for each run and cuvettes were 
rinsed thoroughly with DI water between runs. Buffer background scans without albumin were 
obtained to establish the baseline. All scans were smoothed using the Spectra Manager software 
“Means-Movement” method and the baseline spectra was subtracted from the albumin spectra. Molar 
ellipticity 𝜃  in degree cm2 dmol-1 was calculated according to equation [5] using the mean residue 
weight (MRW) value of 113 Da for albumin 114: 
 𝜃 ! =
! ×!"#
!×!×!"
      [5] 
where 𝜃 is the measured ellipticity at wavelength 𝜆 (mdeg), 𝑐 is the concentration of albumin in 
solution (g/L), and 𝑙 is the path length (cm). Data was visualized by plotting the calculated molar 






4.1 Chapter objective 
Final material characterization in terms of quantification and stability is well established; however, 
both suffer when transferring to in-process analysis. Material concentration and composition can vary 
enormously at different stages of preparation. For a virus, the active ingredient is exposed to culture 
media with composition that varies with time and to fairly elevated temperatures. Following the 
amplification, the virus will be subject to shear stresses, gravitational forces, and osmotic shifts.  
Production and purification processes for ACAM529 have resulted in virus with variable stability. In 
this chapter, various characteristics of three lots of virus were studied to form a baseline for 
subsequent analysis.  
4.2 Materials and methods 
4.2.1 Protein quantification using SDS-PAGE 
To analyze the protein content in each of the viral lots, frozen stocks of Lot A, Lot B, and Lot C were 
quickly thawed at 37°C, serially diluted, then 5 µl was run on SDS-PAGE gels as described in 
Chapter 3. Recombinant human serum albumin (rHSA) dissolved in MilliQ water was used as the 
reference standard. 
4.2.2 TEM imaging 
Transmission electron microscopy (TEM) was used to visualize the structure of ACAM529 in Lot A 
and Lot C as described in Chapter 3. 
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4.2.3 Time course assays 
4.2.3.1 Virus batch differences 
To study the stability profiles of different batches of virus, frozen stocks of Lot A, Lot B, and Lot C 
were quickly thawed at 37°C and diluted 1/100 in triplicate into freshly prepared reference buffer at 
pH 7. The time course assay comparing Lot A to Lot B used incubation temperatures of 2-4°C (in the 
fridge) and 25°C, and samples were taken immediately after (0 hour), 24, 72, and 120 hours after 
diluting the virus to monitor the viral titer. The time course assay comparing Lot B to Lot C used 
incubation temperatures of 2-4°C, 27°C, and 37°C, and samples were taken immediately after (0 
hour), 4, 8, 16, 24, 48, 72, and 120 hours after diluting the virus to monitor viral titer. Plaque assays 
were conducted as described previously in Chapter 3. 
4.2.4 Stability modelling 
4.2.4.1 First order exponential decay model 
The stability profiles of Lot B and Lot C at 2-4°C, 27°C, and 37°C (described in section 4.2.3.1) were 
fit to the following first order decay model: 
 !
!"
 𝑉 𝑡 = −𝑘 ∙ 𝑉(𝑡)      [6] 
𝑉 𝑡 = 𝑉! ∙ 𝑒!!∙!       [7] 
 where V(t) is the viral titer (PFU/ml) at time t (h), V0 is the initial viral titer at 0h, and k is the decay 
rate constant (h-1). The model was fit using the Solver function in Microsoft Excel by minimizing the 
sum of squared differences between the experimental data and model. The constraint that was applied 
was that V0 was held constant for each virus (an assumption that is reasonable at a given pH). To 




𝑘 = 𝐴 ∙ 𝑒!
!!
!∙!        [8] 
where A is the pre-exponential factor (h-1), R is the gas constant (8.314 J mol-1 K-1), and T is the 
temperature (K). An Arrhenius plot (ln(k) vs. T-1) was generated by plotting the linear form of the 
model: 
ln 𝑘 = ln 𝐴 − !!
!∙!
       [9] 
and Ea and A for each virus were calculated using the slope and y-intercept, respectively. 
4.2.4.2 Double decay model 
To better describe biphasic ACAM529 deactivation observed at lower temperatures, a double decay 
model was developed. It was proposed that there are two subpopulations of virus, each undergoing a 
different rate of decay. The first order exponential decay model [7] was adjusted to include an 
additional first order decay component as shown below, and was dubbed the double decay model: 
𝑉(𝑡) = 𝑉! ∙ 𝑒!!!! + 𝑉! ∙ 𝑒!!!!      [10] 
where V1 and V2 are the initial viral titers of subpopulation 1 and 2, respectively, and k1 and k2 are the 
respective decay rate constants. The model can be further simplified: 
 𝑉(𝑡) = 𝑉! ∙ 𝑦! ∙ 𝑒!!!! + 𝑉! ∙ 𝑦! ∙ 𝑒!!!!     [11] 
 𝑉(𝑡) = 𝑉! 𝑦! ∙ 𝑒!!!! + 𝑦! ∙ 𝑒!!!!      [12] 
𝑉(𝑡) = 𝑉! 𝑦! ∙ 𝑒!!!! + (1 − 𝑦!) ∙ 𝑒!!!!     [13] 
where 𝑦! and 𝑦! are the fraction of the population that are subpopulation 1 and 2, respectively, and 
sum to a value of 1. The model was fit to the stability profiles of Lot B and Lot C at 2-4°C (described 
in section 4.2.3.1) using the Solver function in Microsoft Excel by minimizing the sum of squared 




4.3.1 Virus stock albumin content, titer, and imaging 
To compare the protein content in each of the viral lots, SDS-PAGE was conducted and the results 
can be observed in Figure 4.1A. The predominant protein in each lot had a similar molecular weight 
to the albumin standard. Viral proteins were in low quantitates relative to albumin and difficult to 
quantify using the Coomassie stain, even with undiluted samples (Appendix C). The PageRuler 
Prestained protein ladder estimated the correct expected size of albumin (approximately 66 kDa), 
however the PageRuler Unstained protein ladder consistently estimated the size of albumin to be 
higher than 70 kDa. 
The albumin content in each lot was estimated by comparing the intensities of the appropriate band to 
that of the rHSA standard. The most abundant proteins in HSV-1 are capsid protein VP5, which has a 
molecular weight of 149.1 kDa, and tegument protein VP13/14, which has a molecular weight of 73.8 
kDa (see Appendix C). Since these and other viral proteins were in low concentrations, their 
contribution to the intensity of the band for albumin was assumed negligent. Lot A contained 
approximately an order of magnitude more albumin than Lot B, with 0.5-1 g/L and  <0.13 g/L, 
respectively (Figure 4.1B). Lot C, however, had the highest albumin content of the three lots, with 
approximately 8 g/L. The albumin content in each of the lots varied significantly. 
To determine the titer of each of the virus stocks, plaque assays were performed and the results are 
presented in Figure 4.1C. Lot A had a titer of 3.4 ± 0.6 x106 PFU/ml, close to an order of magnitude 
lower than Lot B which had a titer of 2.1 ± 0.4 x 107 PFU/ml. The titer of Lot C was significantly 
higher than the other two lots at 5.2 ± 0.6 x107 PFU/ml. 
TEM was used to observe the physical properties of the virus and to determine whether there were 
physical differences between some of the lots. Lot A and Lot C were imaged and representative 
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images are shown in Figure 4.2 and Figure 4.3, respectively. In Lot A and Lot C, both enveloped 
virus and capsids lacking an envelope (naked capsids) were observed, with the latter being at higher 
prevalence. Enveloped viruses typically appear as round, irregular structures close to 200 nm with 
some displaying a white halo 17,24. The inner structures (capsid and DNA core) are also typically 
visible with adequate penetration by the stain. Many of the enveloped viruses observed in Lot A and 
Lot B did not have highly visible capsids or DNA cores so the stain did not appear to penetrate 
(Figure 4.2B and Figure 4.3C). Many of the enveloped viruses were also observed in clusters (Figure 
4.2B). In many cases however, it was difficult to discern between an enveloped virus and debris. 
Naked capsids are icosahedral and typically appear very regularly shaped and approximately 100 nm. 
Several naked capsids were identified for both Lot A and Lot B and most had electron dense centers, 
indicating the presence of DNA (Figure 4.2A and C, and Figure 4.3A and D). A few displayed more 
uniform colour, suggesting an empty capsid (Figure 4.3B) and some appeared in clusters (Figure 
4.3B). Several naked capsids were observed to be surrounded by an irregular material (Figure 4.2C) 
that could be the tegument layer peeling away 17. Broken capsids were also observed and it was 
possible to see the penton and hexon capsomers that made up the capsid (Figure 4.2D). Due to the 
small size of the virus and difficulty in identifying enveloped virus, it was challenging to accurately 
make quantifiable observations, such as the enveloped virus to naked capsid ratio. Therefore, only 
qualitative observations were made with TEM and both Lot A and Lot C did not show any significant 




   
 
B     C 
Virus  [Albumin] (g/L) 
Lot A 0.5-1 
Lot B <0.13 










Figure 4.1 Analyzing differences in albumin content and titer in ACAM529 Lot A, Lot B, and 
Lot C.  
A. SDS-PAGE gels of each lot of ACAM529. The dilution of each lot is indicated above the lanes. 
rHSA was used as a standard to estimate the albumin content and 5 uL of each sample was loaded. 
PageRuler Prestained (LS) and Unstained (LU) Protein Ladder were used with protein sizes indicated 
(kDa). B. The table summarizes the calculated albumin concentration in each lot of ACAM529, 
approximated by comparing band intensities to the rHSA standard. C. Plot of viral titers of each lot of 







Figure 4.2 TEM imaging of ACAM529 Lot A. 
Black arrows show capsids, White arrows show enveloped virus. Clusters are circled in the respective 







Figure 4.3 TEM imaging of ACAM529 Lot C. 
Black arrows show capsids, white arrows show enveloped virus. Clusters are circled in the respective 
shade. Bars indicate 100 nm.   
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4.3.2 Comparing the stability of ACAM529 lots 
To examine the differences in stability between lots, 120h time course studies were conducted. 
Comparisons of the stability profiles of Lot A and Lot B at 25°C in the first 72 hours revealed they 
were very similar (Figure 4.4A). However, the overall log loss in titer after 120h at 25°C for Lot A 
(0.63 ± 0.10 log loss) was lower than Lot B (0.84 ± 0.10 log loss) (Figure 4.4B). It should be taken 
into account that the calculation for the log loss in titer relies heavily on the first and last point of the 
experiment, whereas the time course assay provides more information about the stability. The time 
course stability profile in Figure 4.4A shows that their profiles were very similar except at 120h, 
where there is an increase in titer for Lot A, though there is relatively high variance in the value. This 
could have been caused by an error in the plaque assay titer and as a result, caused a decreased value 
in the calculated log loss in titer. These results suggest that there was no significant difference in 
stability between Lot A and Lot B. 
Differences between ACAM529 Lot B and Lot C stability were similarly assessed. A time course 
assay was conducted at 27°C for 120h and the results are presented in Figure 4.4C and D. As seen 
previously, there was a steep initial decline in titer in the first 24h with both lots, followed by a less 
steep decline thereafter. It was evident that Lot C, which had 0.89 ± 0.07 log loss in titer, was 




Figure 4.4 Comparing the stability of ACAM529 Lot A, Lot B, and Lot C. 
Lot A and Lot B were diluted into the reference buffer and incubated at 25°C for 120h. Viral stability 
over time was monitored using plaque assays and reported as PFU/ml (A) and the total log loss in 
titer was determined (B). In a second experiment, Lot B and Lot C were diluted into the reference 
buffer and incubated at 27°C for 120h. Viral stability over time was monitored using plaque assays 
and reported as PFU/ml (C) and the total log loss in titer was determined (D). A significant deviation 
(α = 0.05) from Lot B in the same experiment is noted with *.  
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4.3.3 Effect of temperature on ACAM529 stability 
Enveloped viruses, such as ACAM529 are notoriously thermolabile and often experience elevated 
deactivation at higher temperatures. Here, time course assays were conducted to study the effect of 
temperature on the stability of different lots of ACAM529. The results are presented in Figure 4.5 
(the data at 25°C and 27°C are the same as what was presented in Figure 4.4). The data is also 
presented in Appendix D (Figure D.1) in a way that allows for stability comparisons between the 
different lots at a given temperature.  
The stability of each lot of ACAM529 studied here significantly decreased with increased 
temperature. In the first experiment, Lot A had 0.44 ± 0.09 log loss in titer at 2-4°C compared to 0.63 
± 0.10 log loss at 25°C (Figure 4.5A and B). In the same experiment (Figure D.1A and B), Lot B had 
0.45 ± 0.09 log loss in titer at 2-4°C, which was not significantly different from the titer loss observed 
with Lot A, reiterating the results observed in the previous section that these lots have similar stability 
profiles.  
In a separate experiment, the stability of Lot B and Lot C at 2-4°C, 27°C, and 37°C were compared. It 
was evident that Lot B was less stable than Lot C at all temperatures tested (Figure D.1C and D) and 
both lots were significantly more stable at lower temperatures (Figure 4.5C-F). The results also show 
that the difference in stability between the two lots becomes more pronounced at lower temperatures. 
At 2-4°C, the log loss in titer of Lot C was 0.46 ± 0.07 while the log loss in titer of Lot B was 0.77 ± 
0.08. At 27°C, the log loss in titer of Lot C was 0.89 ± 0.07 while the log loss in titer of Lot B was 
1.27 ± 0.11. Finally, at 37°C, the log loss in titer of Lot C was 1.72 ± 0.11 while the log loss in titer of 
Lot B was 1.94 ± 0.11. The processes used to produce Lot C have resulted in a significantly more 




Figure 4.5 Effect of temperature on the stability of ACAM529 Lot A, Lot B, and Lot C.  
Lot A was diluted into reference buffer and incubated at 2-4°C or 27°C for 120h. Viral stability over 
time was monitored using plaque assays and reported as PFU/ml (A) and the total log loss in titer was 
determined (B). In a second experiment, Lot B and Lot C were diluted into the reference buffer and 
incubated at 2-4°C, 27°C or 37°C for 120h. Viral stability over time was monitored using plaque 
assays and reported as PFU/ml (C and E, respectively) and the total log loss in titer was determined 
(D and F, respectively).  
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4.3.4 Stability profile modelling 
4.3.4.1 First order decay kinetics 
Modeling all aspects of viral decay is challenging, as there are numerous potential mechanisms 
involved, each mechanism with their own rate constants. Viral decay, however, typically follows a 
characteristic exponential decay 59,115. The stability profiles of Lot B and Lot C at 2-4°C, 27°C, and 
37°C were fit to the first order decay model expressed in equation [7]. The model was able to 
describe the decay curves at 27°C and 37°C adequately, with data for Lot B fitting slightly better 
overall than Lot C (Figure 4.6A). However at 2-4°C, the decay trend after 24h for both virus, but 
especially Lot C, did not fit the model as well. It was evident that the data better fit the model at 
higher temperatures than at lower temperatures. The V0 values calculated by the model for Lot B 
(1.96 x 105 PFU/ml) and Lot C (5.23 x 105 PFU/ml) were similar to the average experimental titers 
for both viruses at 0h (2.01 ± 0.34 x105 PFU/ml for Lot B, and 5.21 ± 0.56 x105 PFU/ml for Lot C) 
(Figure 4.6B). The k values for both virus increased with increased temperature, indicating an 
increased decay rate with higher temperatures. Also, the k values were lower with Lot C compared to 
Lot B, indicating that the latter decayed at a faster rate. 
The energy of deactivation, Ea (J mol-1), and pre-exponential factor, A (h-1), were calculated using the 
Arrhenius model [8] (Figure 4.7). The energy of deactivation for Lot C (17.78 kJ mol-1) was slightly 
lower than that of Lot B (18.42 kJ mol-1). The pre-exponential factor, however, was twice as high in 
Lot B compared to Lot C (60.91 h-1 compared to 31.07 h-1). This suggests that the factors contributing 


















1.96 x 105 
2.14 x 10-2  9.61 x 108	
27 3.27 x 10-2 5.70 x 108	
37 5.34 x 10-2 6.05 x 108	
Lot C 
2-4 
5.23 x 105 
1.46 x 10-2 1.30 x 1010	
27 2.08 x 10-2 5.10 x 109	
37 3.61 x 10-2 1.57 x109	
 
Figure 4.6 Fitting ACAM529 stability profiles to a first order exponential decay model.  
Virus titer was plot against time and the data was fit to the first order exponential decay 







Virus Lot Ea (kJ mol-1) A (h-1) 
Lot B 18.42 60.91 
Lot C 17.78 31.07 
 
 
Figure 4.7 Arrhenius plot for ACAM529 stability from a first order exponential decay model. 
An Arrhenius plot was generated using the calculated k values at each temperature point (A) and the 
calculated energy of deactivation (Ea) and pre-exponential factor (A) are summarized in the following 
table (B). They were calculated using the slope and y-intercept, respectively.  
 
 51 
4.3.4.2 Double decay model 
To better model the stability profiles of ACAM529 at 2-4°C, a double decay model was tested. The 
stability profiles showed an initial steep decline in titer, followed by a less steep decline thereafter. 
The observed biphasic kinetics could be a result of two species of virus decaying at different rates. To 
reflect this phenomenon, the first order decay model was adjusted to include an additional first order 
decay component, as described in 4.2.4.2, and was dubbed the double decay model [13]. This model 
provided a better fit for the curves at 2-4°C compared to the first order decay model (Figure 4.8). 
Since the kinetics corresponding to k1 and k2 are similar, the larger value was called k1. From the 
parameters, it can be seen that y1, which corresponds to the fraction of the virus population affected 
by the deactivation reaction with k1, was similar for both Lot B and Lot C (0.68 and 0.71, 
respectively). The y2 values (calculated by subtracting y1 from 1) were 0.32 for Lot B and 0.29 for Lot 
C. This suggests the same proportion of virus in both lots experienced each of the two reactions 
described by the model.  
The parameter estimates for k were higher for Lot B than for Lot C, suggesting that some degradation 
pathways were minimized in Lot C. This was also observed with the first order decay model. The k1 
value for Lot B was 4.3 x10-2 h-1, while for Lot C, it was slightly lower at 3.2 x10-2 h-1. Conversely, 
the k2 values were lower than k1 and they differed greatly as Lot B had a value of 5.5 x10-3 h-1, while 
Lot C, had a value of 0 h-1. This suggests that at 2-4°C, both lots contained a smaller subpopulation of 
virus (32% in Lot B and 29% in Lot C) that underwent deactivation at a slower rate, with Lot C 
containing a subpopulation that is stable for the duration of the experiment. The experimental data 
showed a plateau for Lot C after 48h incubation and this could be as a result of the stable sub-













Figure 4.8 Comparing the fit of a first-order decay model with a double decay model for 
ACAM529 stability at 2-4°C. 
The curves shown in Figure 4.6 at 2-4°C are displayed again here for comparison purposes. For the 
double decay model, viral titer was fit to equation [13] (A). The dotted line (…) corresponds to the 
first order exponential decay model: 𝑉 𝑡 = 𝑉! ∙ 𝑒!!∙!, and the solid line (−) corresponds to the 
double decay model: 𝑉(𝑡) = 𝑉! 𝑦! ∙ 𝑒!!!! + (1 − 𝑦!) ∙ 𝑒!!!! . The table summarizes the parameter 
values for the double decay model (B).  







Sum of Squared 
Error (PFU/ml)2	
Lot B 2.05 x 105 0.68 4.3 x 10-2  5.5 x 10-3 2.05 x 108	
Lot C 5.34 x 105 0.71  3.2 x 10-2  0 3.31 x 109	
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4.4 Chapter summary 
In this chapter, various characteristics of three lots of ACAM529 were studied. First, the albumin 
content and titer of each lot was determined and two lots were imaged using TEM. Lot A had up to an 
order of magnitude more albumin content than Lot B. The titer of Lot A was an order of magnitude 
lower than Lot B. Lot C had much more albumin than either of the other two lots and also had 
significantly higher titer. TEM images of Lot A and Lot C showed a high prevalence of naked capsids 
in the samples and some instances of clumping of enveloped viruses and naked capsids. Enveloped 
viruses were difficult to distinguish, as there were not many instances of adequate stain penetration to 
identify the inner viral structures that would identify an enveloped virus. Differences between Lot A 
and Lot C were not discernable using TEM. 
This chapter also explored the stability of the different lots of virus and observed the effects of 
temperature. Lot A and Lot B had similar stabilities at 2-4°C and 25°C. Lot C was significantly more 
stable compared to Lot B at 2-4°C, 27°C, and 37°C, with the difference being more apparent with 
decreasing temperatures.  
Finally, the stability of the ACAM529 was modelled. A first order exponential decay model was 
adequate to describe the stability of Lot B and Lot C at 27°C and 37°C. The parameter estimates for 
the initial viral titer (V0) were close to experimental values and in general, the decay rate constants (k) 
for Lot B were higher than Lot C and higher at higher temperatures. The energy of deactivation 
constants (Ea) were similar for both lots but the pre-exponential factor (A) for Lot B was twice as high 
as Lot C. At lower temperatures (2-4°C), a proposed double decay model, which describes the overall 
decay of two subpopulations of virus following first order exponential decay, was a better fit for the 
stability of Lot B and C. The parameter estimate for the ratio of subpopulations (y1 and y2) was 
similar for both lots and decay rate constants (k1 and k2) were higher for Lot B than Lot C. The value 




Exploring Cell Culture Components for ACAM529 Stabilization Excipients 
5.1 Chapter objective 
Transport of viral specimens in liquid formulation has historically been done in culture media or in 
the presence of serums and extracts, as these environments are optimal for viral viability 116,117. Cell 
culture media and supplements are optimized to encourage cell growth and product production, but 
they also serve the function of protecting fragile cellular membranes from various stresses. Chemical 
stresses such as osmolarity, pH and oxidative stresses, as well as physical stresses such as shear 
stresses, are all concerns during cell culture and various compounds are added to mitigate these 
stresses 118,119. In this chapter, culture media and additives associated with virus production were 
assayed for their stabilizing properties of ACAM529 in liquid formulation. The media and additives 
studied were fetal bovine serum (FBS), recombinant human serum albumin (rHSA), OptiPro serum-
free media (SFM), cholesterol lipid concentrate solution (CLC), and Pluronic F68 (PF68).  
5.2 Materials and methods 
5.2.1 Time course assays 
5.2.1.1 Effect of FBS 
To study the stability of ACAM529 in the presence of FBS, virus Lot B was quickly thawed at 37°C 
and diluted 1/100 in triplicate into freshly prepared reference buffer with or without 0.01%, 0.1%, 
1%, 10%, or 50% (v/v) characterized FBS lot AAF204951 of Canadian origin (HyClone) (see 
Appendix E), then incubated at 27°C. Samples were taken immediately after (0 hour), and 24, 72, and 
120 hours after diluting the virus to monitor the viral titer using plaque assays, described in Chapter 3. 
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5.2.1.2 Effect of rHSA  
To study the stability of ACAM529 in the presence of albumin, frozen stocks of Lot B and Lot C 
were quickly thawed at 37°C and diluted 1/100 in triplicate into freshly prepared buffer. The time 
course assay of Lot B with added rHSA compared to Lot C used the reference buffer with or without 
1 g/L rHSA (Cellastim, Invitria) at pH 7, and incubation was carried out at either 2-4°C or 25°C. The 
time course assay analyzing the effects of different concentrations of rHSA on the stability of Lot B 
used the reference buffer with or without 0.05 g/L, 0.5 g/L, or 5 g/L rHSA at pH 7 and incubation 
temperatures of 2-4°C or 27°C. Samples were taken immediately after (0 hour), 24, 72, and 120 hours 
after diluting the virus to monitor the viral titer using plaque assays as described previously in 
Chapter 3. 
5.2.1.3 Effect of OptiPro SFM culture media 
To study the stability of ACAM529 in the presence of OptiPro SFM, virus Lot B was quickly thawed 
at 37°C and diluted 1/100 in triplicate into freshly prepared reference buffer with or without 10% 
OptiPro SFM (Gibco) or 10% conditioned OptiPro SFM (OptiPro SFM removed from a four-day 
culture of Vero CCL-81 cells and passed through a 0.2 µm filter), then incubated at 27°C. Samples 
were taken immediately after (0 hour), and 24, 72, and 120 hours after diluting the virus to monitor 
the viral titer using plaque assays as described in Chapter 3.  
5.2.1.4 Effect of CLC 
Two runs were completed to test the effects of a cholesterol solution. In both runs, virus Lot B was 
quickly thawed at 37°C and diluted 1/100 in triplicate into the freshly prepared buffers. For the first 
run, the buffers tested were the reference buffer with or without 1x CLC (Gibco). For the second run, 
the buffers tested were the reference buffer with or without 0.1x or 0.5x CLC. Both runs were 
incubated at 27°C and samples were taken immediately after (0 hour), and 24, 72, and 120 hours after 
diluting the virus to monitor the viral titer using plaque assays, described in Chapter 3.  
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5.2.1.5 Effect of PF68 
To study the stability of ACAM529 in the presence of PF68, frozen virus Lot B was quickly thawed 
at 37°C and diluted 1/100 in triplicate into freshly prepared reference buffer at pH 7 with or without 
0.001%, 0.01%, 0.1%, and 1% (w/v) PF68 (Gibco), then incubated at 27°C. Samples were taken 
immediately after (0 hour), and 120 hours after diluting the virus to monitor the viral titer using 
plaque assays as described in Chapter 3.  
5.2.2 Stability modeling of ACAM529 with buffer containing FBS 
5.2.2.1 First order exponential decay model 
The stability profiles of Lot B in buffer with or with out 0.01%, 0.1%, 1%, 10%, or 50% FBS 
(experiment described in section 5.2.1.1) were fit to the first order decay model in equation [7] using 
R 107–113. The complete code is presented in Appendix F. 
5.2.2.2 Zero order decay model 
The stability profiles of Lot B in buffer with or with out 0.01%, 0.1%, 1%, 10%, or 50% FBS 
(experiment described in section 5.2.1.1) were fit to the following zero order decay model: 
!
!"
𝑉(𝑡) = −𝑘       [14] 
𝑉(𝑡) = 𝑉! − 𝑘𝑡       [15] 
where V(t) is the viral titer (PFU/ml) at time t (h), V0 is the initial viral titer at 0h,and  k is the decay 




5.2.3 CD spectrometry 
5.2.3.1 Thermal stress effect on rHSA structure 
The effects of thermal stresses on rHSA conformation were studied using circular dichroism (CD) 
spectrometry. Solutions were made by dissolving rHSA in 10 mM phosphate (Sigma-Aldrich) buffer 
at pH 7, at concentrations of 20 g/L and 2 g/L, then filtered through a 0.2 µm filter. Solutions were 
split into 1 ml aliquots and each concentration was either: frozen at -80°C for one hour, then thawed 
at 37°C before incubating on ice; incubated at 56°C for half an hour, then incubated on ice; or 
incubated at 56°C for half an hour, frozen at -80°C for one hour, then thawed at 37°C before 
incubating on ice. A control sample that was incubated on ice for the duration of all incubation times 




5.3.1 Effect of FBS on ACAM529 stability 
To study the stabilizing effects of FBS, various concentrations of FBS were added to the reference 
buffer and the stability of ACAM529 at 27°C was monitored using the time course assay. The FBS 
used in these studies contained approximately 19 g/L BSA (see Appendix E, Figure E.1). There was 
0.56 ± 0.10 log loss in virus titer with buffer containing 50% FBS, 0.29 ± 0.08 log loss with 10% 
FBS, 0.24 ± 0.08 log loss with 1% FBS, 0.30 ± 0.09 log loss with 0.1% FBS, 0.43 ± 0.09 log loss 
with 0.01% FBS, and 0.61 ± 0.06 log loss in the reference buffer control (Figure 5.1). The addition of 
any concentration of FBS to the buffer performed equal to or better than the control without FBS.  
The addition of 0.01%-10% (v/v) FBS to the buffer resulted in significant improvements to the viral 
stability compared to the control with no FBS. Minimal loss in titer occurred with the buffer 
containing 1% FBS and as the concentration of FBS was decreased or increased from this point, the 
stabilizing effects of FBS were less pronounced. The log loss in titer after 120h of the virus in buffer 
containing 50% FBS was not significantly different from the control. The stability profiles of the 




Figure 5.1 Effect of different concentrations of added FBS on ACAM529 stability. 
ACAM529 Lot B was diluted into the reference buffer with or without 0.01%, 0.1%, 1%, 10% or 
50% FBS, then incubated at 27°C. Viral stability over time was monitored using plaque assays and 
reported as PFU/ml (A). The total log loss in titer (B) was determined and buffers which yielded a 




5.3.1.1 Modelling the stability profile of ACAM529 in buffer containing FBS 
Several of the viral decay curves observed thus far at conditions above ambient temperatures have 
followed a first order exponential decay trend. However in this study, buffers containing 0.1%-10% 
FBS appeared to follow a linear trend over a period of 120 hours as shown in Figure 5.1A. To explore 
this further, the data was fit to the first order exponential decay model discussed in Chapter 4 
(equation [7]), as well as a zero order decay model (equation [15]). As shown in Figure 5.2, the 95% 
confidence intervals for the zero order models of the 0.1%-10% FBS-containing buffers are much 
narrower than the control, and the R2 values are also higher, showing a better fit. The buffers with 
FBS concentrations on the higher and lower end (50% and 0.01%, respectively) had 95% confidence 
intervals relatively wider than the other concentrations of FBS but still narrower than the control. 
With either model, it is clear that the buffer containing 1% FBS resulted in more stable virus as the 𝑘 















(PFU ml-1 h-1) 
Adjusted 
R2 
Reference Buffer 1.70 x 105 12.7 x 10-3 1.58 x 105 1048.0 0.8804 
+ 0.01% FBS 1.81 x 105 8.97 x 10-3 1.73 x 105 963.1 0.919 
+ 0.1% FBS 2.03 x 105 5.68 x 10-3 2.00 x 105 834.04 0.9922 
+ 1% FBS 2.05 x 105 4.30 x 10-3 2.03 x 105 698.08 0.994 
+ 10% FBS 1.98 x 105 5.25 x 10-3 1.97 x 105 791.93 0.987 
+ 50% FBS 1.94 x 105 9.64 x 10-3 1.89 x 105 1160.7 0.9667 
 
Figure 5.2 Fitting ACAM529 stability with different concentrations of FBS to decay curves.  
Curves from Figure 5.1 were fit to first order exponential and zero order decay curves (A). The first 
order exponential decay model is: V(t) = V0 e(-kt), where V(t) is the viral titer (PFU/ml) at time t (h), V0 
is the initial viral titer at 0h, and k is the decay rate constant (h-1). The zero order decay model is:  
V(t) = V0 – kt, where k is the decay rate constant (PFU ml-1 h-1). The shaded region in each of the 
plots indicates the 95% confidence interval for the zero order decay model. The table summarizes the 
parameter values and the adjusted R2 value as calculated using R for the linear model fit (B).  
 
 62 
5.3.2 Effect of adding rHSA to final purified ACAM529 on viral stability 
Albumin is the most abundant protein in FBS and it was found in relatively high concentration in the 
more stable lot of ACAM529. To determine whether it can be used as a stabilizing excipient, rHSA 
was added to the ACAM529 reference buffer and a time course study was conducted. ACAM529 Lot 
B, which had minimal albumin (Figure 4.1), was diluted into reference buffer containing 1 g/L rHSA 
and the stability of the virus was monitored and compared to that of Lot C. At 25°C, the presence of 1 
g/L rHSA lead to significantly higher log loss in titer after 120h for Lot B compared to the control 
with no rHSA, however their stability profiles appeared to be very similar after 24h (Figure 5.3). At 
2-4°C, there was also a steeper initial decline in titer for Lot B with 1 g/L rHSA in the first 24h 
however subsequently there was a less steep decline in titer. The pattern of decay after 24h appeared 
linear and was more similar to that of Lot C than Lot B without rHSA present. In fact, over the 120h 
period studied here, there was a significant improvement in the log loss in titer of Lot B with the 
addition of 1 g/L rHSA at 2-4°C compared to the control but the log loss in titer was not as low as 
that of Lot C. The addition of 1 g/L rHSA appeared to offer stability to the virus at lower 
temperatures but was detrimental at higher temperatures.  
When different concentrations of rHSA were added to the reference buffer, the stability of Lot B was 
again significantly improved at 2-4°C with concentrations of 0.05-5 g/L rHSA and significantly 
poorer at 27°C with the addition of 0.5 g/L and 5 g/L rHSA (Figure 5.4). The stability profiles at 2-
4°C were very similar for all samples with rHSA and did not depend on the concentration of rHSA. 
The stability at 27°C, on the other hand, decreased with increasing concentrations of rHSA, where the 
steepest decline in viral titer occurred in the first 24h in the presence of 5 g/L rHSA. However, with 
the addition of 0.05 g/L rHSA, the stability of Lot B at 27°C was significantly improved when 
compared to the control with no rHSA. At lower temperatures, concentrations of rHSA ranging 
between 0.05 g/L – 5 g/L aided in viral stability, but at temperatures closer to ambient conditions, 
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small amounts of rHSA had a protective effect on the virus, whereas increased concentrations 




Figure 5.3 Effect of added rHSA on ACAM529 stability.  
ACAM529 Lot B was diluted into the reference buffer with or without 1 g/L rHSA and Lot C was 
diluted into reference buffer, then both were incubated at 2-4°C or 25°C for 120h. Viral stability over 
time was monitored using plaque assays and reported as PFU/ml (A). The total log loss in titer (B) 
was determined and a significant deviation (α = 0.05) from the log loss at 25°C is noted with *, and a 





Figure 5.4 Effect of different concentrations of added rHSA on ACAM529 stability. 
ACAM529 Lot B was diluted into the reference buffer with or without 0.05 g/L, 0.5 g/L, or 5 g/L 
rHSA and incubated at 2-4°C or 27°C for 120h. Viral stability over time was monitored using plaque 
assays and reported as PFU/ml (A). The total log loss in titer (B) was determined and a significant 
deviation (α = 0.05) from the log loss at 27°C is noted with *, while a significant deviation from the 




5.3.3 Effect of thermal stress on rHSA structure 
The albumin found in FBS compared to albumin found in purified virus may not have the same 
structural characteristics and one cause is from experiencing different thermal stresses. For example, 
FBS is often heat-inactivated prior to use, while purified virus is frozen for storage, and then thawed 
when needed. To study whether thermal stresses due to heating or freezing and thawing cause 
secondary structure changes in rHSA, far UV CD spectrometry was used. The CD spectra for rHSA 
subjected to heat-inactivation (56°C for 0.5h) and/or a freeze-thaw cycle (-80°C for 1h then 37°C 
until thawed) were very similar to that of rHSA incubated on ice at both 2 g/L and 20 g/L rHSA 
(Figure 5.5). Two strong negative peaks corresponding to alpha helical structure at approximately 208 
nm and 222 nm were evident in all conditions tested and there were no discernable differences in the 
intensities between samples, indicating similar rHSA secondary structure characteristics. Subjecting 2 
g/L and 20 g/L rHSA to the different temperature incubation conditions did not cause any permanent 




Figure 5.5 Far UV CD spectrometry to analyze the structural effects of thermal stresses on 
rHSA. 
The effect of heat inactivation (56°C for 0.5h), a freeze-thaw cycle (-80°C for 1h, then 37°C until 
thawed), or a combination of both, on the secondary structure of rHSA was analyzed using CD 




5.3.4 Effect of OptiPro SFM culture media on ACAM529 stability 
OptiPro SFM is used to culture the complementary Vero cells for ACAM529 production 12 and it 
replaces components of FBS so that it is not needed in culture. To assess whether OptiPro SFM 
contains ACAM529 stabilizers, a time course study was conducted. With the addition of 10% (v/v) 
OptiPro SFM to the reference buffer, no significant changes to viral stability were observed at 27°C 
when compared to the control over a period of 120 hours (1.05 ± 0.09 log loss compared to 1.03 ± 
0.10 log loss) (Figure 5.6). Conditioned OptiPro SFM was also assayed in the same experiment. With 
the addition of 10% (v/v) conditioned OptiPro SFM, a slight improvement to viral stability was 
observed after 120 hours, with a 0.70 ± 0.13 log loss in titer (Figure 5.6). The initial titer at 0 hours 
was slightly lower for the buffer with 10% conditioned OptiPro compared to the control (Figure 5.6B) 
and this would contribute to the lower overall log loss in titer seen in Figure 5.6C. However it should 




Figure 5.6 Effect of fresh and conditioned OptiPro SFM on ACAM529 stability.  
ACAM529 Lot B was diluted into the reference buffer with or without 10% fresh OptiPro serum-free 
media (SFM) or 10% conditioned OptiPro SFM (filter sterilized media from a 4-day culture of Vero 
CCL81 cells), then incubated at 27°C. Viral stability over time was monitored using plaque assays 
and reported as PFU/ml (A). The initial and final titers are also displayed as a boxplot (B) to show 
that the titer of the virus in the buffer containing 10% conditioned OptiPro SFM at 120h was higher 
than the control at a significance level of α = 0.1. The total log loss in titer (C) was determined and 
buffers which yielded a significant deviation (α = 0.05) from the control (reference buffer) are noted 
with *.  
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5.3.5 Effect of CLC on ACAM529 stability 
OptiPro SFM is supplemented with CLC for ACAM529 production 12. CLC is an animal- and 
protein- free chemically defined lipid solution often used for culturing lipid-dependent cell lines 
120,121. To study whether CLC could protect the virus from degradation at 27°C, time course assays 
were conducted. When 1x CLC was added to the reference buffer, it had a deleterious effect on viral 
stability. There was a steep decline in virus titer in the first 24h and titers were too low to quantify 
after this period (Figure 5.7A). With lower concentrations of CLC (0.5x and 0.1x), there was still a 
significant decrease in the stability of the virus, with a large drop in titer again occurring in the first 
24 hours (Figure 5.7B and C). The loss in titer after 120 hours for solutions containing CLC were 




Figure 5.7 Effect of CLC on ACAM529 stability. 
ACAM529 Lot B was diluted into the reference buffer with or without 1x CLC then incubated at 
27°C. Viral stability over time was monitored using plaque assays and reported as PFU/ml (A). Titers 
for the CLC-containing buffer were unquantifiable beyond 24h. In a second experiment, ACAM529 
Lot B was diluted into the reference buffer with or without 0.1x or 0.5x CLC then incubated at 27°C. 
Viral stability over time was monitored using plaque assays and reported as PFU/ml (B). The total log 
loss in titer (C) was determined and buffers which yielded a significant deviation (α = 0.05) from the 




5.3.6 Effect of PF68 on ACAM529 infectivity and stability 
Pluronic F68 (PF68) is a non-ionic surfactant that is widely used as a shear protectant in cell culture 
at a concentration of 0.1%. To study whether PF68 has stabilizing properties for ACAM529, viral 
stability of Lot B in the reference buffer with the addition of 0.001%, 0.01%, 0.1%, or 1% (w/v) PF68 
after 120h at 27°C was assayed and the results are presented in Figure 5.8. Initial viral titers at 0h 
were similar with or without PF68 at all concentrations indicating no significant effect to viral 
infection. After 120h, the titer of samples containing 0.01%-0.1% PF68 were higher than the control, 
with higher titers achieved with higher concentrations of PF68. The overall log loss in titer was 
significantly decreased compared to the control, where the buffer with 0.01% PF68 had 0.44 ± 0.06 
log loss, 0.1% PF68 had 0.38 ± 0.09 log loss and the control with no PF68 had 0.63 ± 0.08 log loss. 
With 0.001% PF68, there was no significant difference in titers compared to the control. At a 
concentration of 1% PF68, well above the critical micelle concentration (CMC) of 0.4%, the total log 
loss in titer after 120h significantly increased to 1.47 ± 0.08. Maximal stability was achieved at a 




Figure 5.8 Effect of different concentrations of PF68 on ACAM529 stability. 
ACAM529 Lot B was diluted into the reference buffer with or without 0.001%, 0.01%, 0.1%, or 1% 
Pluronic F68 (PF68) and incubated at 27°C for 120h. Viral titer at 0h and 120h was quantified using 
plaque assays and reported as PFU/ml (A). The total log loss in titer (B) was determined and a 




5.4 Chapter summary 
In this chapter, various defined and complex solutions used in cell culture were assayed for their 
stabilizing effects on ACAM529. First, FBS and an albumin supplement, rHSA were studied. FBS 
significantly improved the stability of ACAM529 Lot B at 27°C at concentrations ranging between 
0.01%-10%, with a maximum stability achieved using 1% FBS. With 50% FBS, there was no 
significant change to virus stability compared to the control. The addition of 0.05-5 g/L rHSA to 
purified ACAM529 Lot B improved virus stability at 2-4°C in a concentration-independent manner. 
However, at 27°C, 0.5-5 g/L rHSA significantly reduced the stability, where increasing 
concentrations of rHSA lead to decreasingly stable virus. Low concentrations of rHSA (0.05 g/L) 
improved stability at 27°C. At both temperatures, the stability of Lot C was significantly better than 
Lot C with or without 1 g/L rHSA. Thermal stresses to rHSA due to freeze-thaw and/or heat 
inactivation were assessed using CD spectrometry however no permanent secondary structure 
changes to rHSA were observed. 
The effects of other components used in cell culture were also studied. The addition of 10% 
conditioned OptiPro SFM resulted in a slight improvement to stability over a period of 120 hours at 
27°C, however the same amount of fresh medium resulted in no change to stability. The addition of 
0.1x-1x CLC supplements to the buffer resulted in dramatic decreases to ACAM529 stability at 27°C, 
especially in the first 24h. Lastly, PF68 at concentrations below the CMC, significantly improved 




Screening Excipients for ACAM529 Stability 
6.1 Chapter objective 
Stabilization formulations have been developed for a number of vaccines, leading to a library of 
commonly used excipients. Due to differences in structure, composition, and complexity between 
different vaccines, as well as an incomplete understanding of the mechanisms behind the stabilization 
properties of some excipients, formulations that work for one vaccine may not necessarily work for 
another. Even among enveloped virus, differences can arise in membrane composition and 
glycoprotein structure 100. Therefore, intensive screening studies are often required for each specific 
vaccine. Sanofi Pasteur’s stabilization buffer, used throughout this work as a reference buffer, was 
developed partially with screening studies (Patent US 20150150964 A1) 122. In this chapter, various 
conditions and excipients that have been implicated in enhancing the stability of protein and lipid-
based products, were investigated for ACAM529 stabilization. The effect of pH, trehalose, L-
arginine, and Eagle’s minimum essential medium (MEM) non-essential amino acid solution (NEAA) 
were tested in liquid formulation. 
6.2 Materials and methods 
6.2.1 Effect of buffer pH 
To study the stability of ACAM529 at lower buffer pH, virus Lot A was quickly thawed at 37°C and 
diluted 1/100 into freshly prepared reference buffer adjusted to pH 5, pH 6, or pH 7 with HCl and 
incubated at room temperature. Samples were taken immediately after (0 hour), and 2, 10, 24, 48, 72, 
96, and 120 hours after diluting the virus to monitor the viral titer using plaque assays in triplicate as 
described in Chapter 3. 
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6.2.2 Effect of trehalose and interaction effects between pH and the disaccharide 
To study the interaction effect between pH and the sugar, virus Lot A was quickly thawed at 37°C 
and diluted 1/100 in triplicate into freshly prepared reference buffer at pH 6 or pH 7, or in the 
reference buffer with the 10% sucrose replaced with 10% trehalose (Sigma-Aldrich) at pH 6 or pH 7, 
then incubated at 27°C. Samples were taken immediately after (0 hour), and 24, 72, and 120 hours 
after diluting the virus to monitor the viral titer using plaque assays as described above. 
To study the effects of increasing concentrations of trehalose, virus Lot C was quickly thawed at 
37°C and diluted 1/100 into freshly prepared reference buffer at pH 6, or in the reference buffer with 
the 10% sucrose replaced with either 10%, 15% or 30% (w/v) trehalose at pH 6, then incubated at 
27°C. Samples were taken immediately after (0 hour), and 2, 10, 24, 48, 72, 96, and 120 hours after 
diluting the virus to monitor the viral titer using plaque assays as described above.  
6.2.3 Effect of adding L-arginine 
To study the stability of ACAM529 in the presence of L-arginine, virus Lot B was quickly thawed at 
37°C and diluted 1/100 in triplicate into freshly prepared reference buffer at pH 7, or in the reference 
buffer with the addition of 0.01 M or 0.1 M L-arginine (Sigma-Aldrich) at pH 7, then incubated at 
27°C. It should be noted that in the process of adjusting to pH 7 for the reference buffer containing 
0.01 M and 0.1 M L-arginine, significant amounts of hydrochloric acid (HCl) were required. The 
concentration of chloride ions was increased by 40 mM and 220 mM, respectively. Samples were 
taken immediately after (0 hour), and 24, 72, and 120 hours after diluting the virus to monitor the 
viral titer using plaque assays as described above.  
6.2.4 Effect of adding NEAA 
To study the stability of ACAM529 in the presence of NEAA, virus Lot B was quickly thawed at 
37°C and diluted 1/100 in triplicate into freshly prepared reference buffer at pH 7, or in the reference 
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buffer with the addition of 0.1x, 0.5x, or 1x NEAA (Sigma-Aldrich) at pH 7, then incubated at 27°C. 
Samples were taken immediately after (0 hour), and 24, 72, and 120 hours after diluting the virus to 
monitor the viral titer using plaque assays as described above. 
6.3 Results 
6.3.1 Effect of changes in buffer pH on ACAM529 stability 
To determine the effect that low pH environments have on ACAM529, the pH of the reference buffer 
was adjusted to either pH 7, pH 6 or pH 5 and the infectivity and stability of Lot A diluted in this 
buffer was studied. ACAM529 infectivity was assessed by the viral titers at 0h (Figure 6.1A) and it 
was evident that the low pH buffer significantly improved initial infectivity. The titer of the virus in 
the reference buffer at pH 5 was 3.9 ± 0.5 x 104 PFU/ml whereas the same buffer at pH 7 yielded a 
titer of 2.9 ± 0.4 x 104 PFU/ml. When lowered to pH 6, the viral titer (3.5 ± 0.9 x 104 PFU/ml) was 
not significantly different from that at pH 7, though there was an increased variability in the data. 
To determine whether the reference buffer at pH 5 would be suitable for long-term stability, a 120h 
time course stability study at room temperature was conducted. Though the pH 5 buffer had an 
increased titer at the 0h time point, it was clear that the stability of the virus deteriorated much more 
quickly within the first 24h when compared to the pH 6 and pH 7 buffers (Figure 6.1B). The titer at 
120h was 7.9 ± 1.2 x 103 PFU/ml for the pH 5 buffer, which was significantly lower than that of the 
pH 7 and 6 buffers which were 1.2 ± 0.2 x 104 PFU/ml and 1.4 ± 0.2 x 104 PFU/ml, respectively. The 
instability of the virus in the acidic buffer is clear from the overall log loss in titer (Figure 6.1C). The 
viral stability and overall loss in titer were not significantly different in the pH 7 and pH 6 buffers, 
suggesting that ACAM529 is tolerant of conditions in this pH range, but more acidic conditions result 




Figure 6.1 Effect of buffer pH on ACAM529 infectivity and stability.  
ACAM529 Lot A was diluted into the reference buffer adjusted to pH 5, pH 6, or pH 7 and viral titer 
in PFU/ml was determined using plaque assays (A). The titer at pH 5 was slightly higher than at pH 7 
(α = 0.1). Viral stability at room temperature was monitored using plaque assays and reported as 
PFU/ml (B). The total log loss in titer was determined (C). Buffers that yielded a significant deviation 




6.3.2 Effect of trehalose on ACAM529 stability 
Trehalose is an increasingly popular disaccharide used in vaccine formulation and it has been shown 
to demonstrate superior properties over sucrose in some cases 55,66,67,69,70,72,76,77. To study the effects of 
trehalose on ACAM529 stability, the disaccharide used in the reference buffer, 10% (w/v) sucrose, 
was replaced with 10% (w/v) trehalose. In addition, the effect of reducing the pH to 6 from pH 7 was 
also analyzed to look for any interaction effects between trehalose and buffer pH. The stability 
profiles of ACAM529 in buffer containing 10% sucrose were very similar to those containing 10% 
trehalose at 27°C (Figure 6.2A) and there was no significant difference in the overall loss of viral titer 
after 120 hours (Figure 6.2B). Trehalose offered the same level of stability to ACAM529 as sucrose 
between pH 6-7. The effect of increasing the concentration of trehalose at pH 6 also did not have a 
significant effect on the stability at 27°C (Figure 6.3A) or overall loss in titer after 120h (Figure 6.3B) 
when compared to the control. There was a 0.26 ± 0.12 log loss in titer for the buffer containing 10% 
trehalose, 0.31 ± 0.10 log loss for 15% trehalose, 0.34 ± 0.12 log loss for 30% trehalose, and 0.31 ± 




Figure 6.2 Effect of trehalose and pH on ACAM529 stability.  
ACAM529 Lot A was diluted into the reference buffer at pH 7 or pH 6, or in the reference buffer with 
the 10% sucrose replaced with 10% trehalose at pH 7 or pH 6, then incubated at 27°C. Viral stability 
over time was monitored using plaque assays and reported as PFU/ml (A). The total log loss in titer 
(B) was determined and buffers which yielded a significant deviation (α = 0.05) from the control 




Figure 6.3 Effect of increasing concentrations of trehalose on ACAM529 stability. 
ACAM529 Lot C was diluted into the reference buffer at pH 6, or in the reference buffer with the 
10% sucrose replaced with either 10%, 15% or 30% trehalose at pH 6, then incubated at 27°C. Viral 
stability over time was monitored using plaque assays and reported as PFU/ml (A). The total log loss 
in titer (B) was determined and buffers which yielded a significant deviation (α = 0.05) from the 




6.3.3 Effect of L-arginine and NEAA on ACAM529 stability 
Amino acids have been implicated in biological product stabilization due to their buffering 
capabilities 58, antioxidant properties 85,86, and generally favourable interactions with biochemical 
compounds 76,81,123. L-arginine has been used extensively as an excipient to stabilize proteins 80,82 and 
to discourage protein aggregation 83,124. To study the stabilizing effect of L-arginine on ACAM529, a 
time course assay was conducted. The effect of 0.01 M and 0.1 M L-arginine on virus stability at 
27°C was not significantly different from the reference buffer control (Figure 6.4). There was no 
significant difference between the overall log loss in titer between the buffer with 0.1 M L-arginine, 
0.01 M L-arginine, and the control (0.80 ± 0.12 log loss, 0.61 ± 0.09 log loss, and 0.66 ± 0.17 log 
loss, respectively). During buffer preparations, the addition of L-arginine resulted in a more alkaline 
solution when compared to the control and this necessitated the addition of a significant amount of 
HCl to adjust the buffer to pH 7. The final 0.1 M L-arginine-containing buffer had ~0.38 M Cl- ions, 
more than double the original buffer (~0.16 M), while the 0.01 M arginine-containing buffer had 
~0.20 M Cl- ions. This doubling of the Cl- ions, and ultimately altering the ionic strength of the 
buffer, did not negatively affect ACAM529.  
Eagle’s minimum essential medium (MEM) non-essential amino acid solution (NEAA) is a 
chemically defined amino acid cell culture supplement shown to have membrane stabilization 
properties 123. The effect of NEAA on ACAM529 stability at 27°C was also investigated. It was found 
that there was no significant change to the stability profiles (Figure 6.5A) or overall loss in titer after 
120h (Figure 6.5B) with the 1x, 0.5x or 0.1x concentrations of NEAA when compared to the 
reference buffer control (0.64 ± 0.10 log loss, 0.69 ± 0.14 log loss, and 0.70 ± 0.10 log loss, 





Figure 6.4 Effect of different concentrations of L-arginine on ACAM529 stability.  
ACAM529 Lot B was diluted into reference buffer with or without 0.01 M or 0.1 M L-arginine, then 
incubated at 27°C. Viral stability over time was monitored using plaque assays and reported as 
PFU/ml (A). The total log loss in titer (B) was determined and buffers which yielded a significant 





Figure 6.5 Effect of different concentrations of NEAA on ACAM529 stability. 
ACAM529 Lot B was diluted into the reference buffer with or without 0.1x, 0.5x, or 1x Eagle’s 
minimum essential medium non-essential amino acid solution (NEAA), then incubated at 27°C. Viral 
stability over time was monitored using plaque assays and reported as PFU/ml (A). The total log loss 
in titer (B) was determined and buffers which yielded a significant deviation (α = 0.05) from the 
control buffer (reference buffer) are noted with *.  
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6.4 Chapter summary 
In this chapter, pH, trehalose, L-arginine, and NEAA were investigated for ACAM529 stabilization. 
Although an acidic buffer (pH 5) caused an improved initial infectivity of the virus when titered with 
the plaque assay, it had a negative impact on long-term stability compared to buffers in the range of 
pH 6-7. The replacement of 10% (w/v) sucrose with 10-30% (w/v) trehalose in the reference buffer 
did not result in changes to viral stability at pH 6-7 at 27°C. The addition of 0.01-0.1 M L-arginine 
(along with the resulting increase in buffer ionic strength with the addition of Cl- ions) and 0.1x-1x 





Stability of the candidate vaccine ACAM529, especially during purification processes, is a major 
production issue. This work aimed to study the vaccine candidate and identify excipients to improve 
the effectiveness of the stabilization buffer.  
7.1 ACAM529 production and purification processes have resulted in virus with variable titer, 
albumin content, and stability 
The titer of Lot B (2.1 ± 0.4 x 107 PFU/ml) was an order of magnitude higher than that of Lot A (3.4 
± 0.6 x 106 PFU/ml), and it also had an order of magnitude less albumin (<0.13 g/L and 0.5-1 g/L, 
respectively). When the stability of the two lots were examined, they had similar stability profiles and 
losses in titer during a 120h period at 2-4°C and 25°C. Lot C had further improved titers (5.2 ± 0.6 x 
107 PFU/ml) compared to Lot B and was significantly more stable at 2-4°C, 27°C, and 37°C, with the 
difference being more apparent with decreasing temperatures; however, higher levels of albumin 
(approximately 8 g/L) were present. 
7.2 ACAM529 stability modelling 
Modelling the stability profiles of the virus is beneficial as it allows for quantitative comparisons of 
the stabilities of the virus lots and provides information about the mechanisms behind the 
deactivation. However, modelling all aspects of viral decay is challenging, as there are numerous 
potential mechanisms involved in virus degradation, with each mechanism having its own rate 
constants. Viral decay, typically follows a characteristic exponential decay 59,115 so the stability 
profiles were first modeled with a first order decay model. The model estimated initial virus titers, V0, 
similar to the experimental values and it also revealed that the reaction rate constant, k, increased with 
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temperature and was generally higher for Lot B than Lot C. This was consistent with the earlier 
findings that increased temperature lead to decreased stability and Lot B was less stable than Lot C.  
The Arrhenius model describes the dependence of the reaction rate constant on temperature and it can 
be used to estimate Ea and A. The energy of deactivation, Ea, refers to the energy required for the 
chemical reaction to proceed forward. In this case, a lower value for Ea would suggest the virus was 
less stable since less energy is required for deactivation. Though Lot C was found to be more stable 
than Lot B, the Ea value was slightly higher for Lot B (18.42 kJ mol-1 for Lot B and 17.78 kJ mol-1 for 
Lot C). The larger difference was found with the pre-exponential factor, A. The value for A was twice 
as high in Lot B compared to Lot C (60.91 h-1 and 31.07 h-1, respectively). 
It should be noted that the estimation of Ea and A for Lot B and Lot C relied on the data obtained 
from the stability profiles at 2-4°C, which was observed to not fit the model as well as at 27°C and 
37°C. It would be beneficial to obtain more accurate estimates of these parameters by repeating the 
time course assays at more temperature conditions, especially above 20°C since the stability of the 
virus at ambient conditions is of interest. 
Analyzing the Ea and A values for ACAM529 may shed light on the mode of action of different 
excipients. It would be of interest to repeat the time course studies at multiple temperature conditions 
with FBS and PF68, both of which improved the stability at 27°C, and determine the changes to Ea 
and A. 
The first order decay model was insufficient to model the ACAM529 stability profiles at 2-4°C as the 
virus experienced a steep initial decline in titer, followed by a less steep decline thereafter. This 
biphasic inactivation was also observed by Higashikawa and Chang with two retrovirus vectors 125. 
The double decay model proposed here was able to describe the stability profiles at the lower 
temperature better than the first order decay model. The model proposes the presence of two 
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subpopulations of virus, each undergoing first order decay at different decay rates. Both Lot B and 
Lot C were found to have similar proportions of virus subpopulations undergoing the two different 
rates of decay, where Lot C had the lower decay rate constants in each subpopulation. The smaller 
subpopulation (29%) in Lot C was found to have a rate constant of 0 h-1, which indicated a stable 
subpopulation of virus. The cause for the emergence of two subpopulations is unclear. It could be a 
result of production protocols, a remnant of undergoing freeze-thaw cycles, or how the virus interacts 
with the contents of the liquid solution. Achieving the conditions that render the 29% subpopulation 
of Lot C to experience a low rate of deactivation would be ideal for ACAM529 stability. 
It is possible that the improved fit of the double decay model could be due to a phenomena that there 
are indeed two species of virus (or more, which can be modelled by adding more parameters), 
however it is also possible that the increased number of parameters allowed for the better fit. More 
data is necessary to validate this model.  
It is important to note that the viral stability profiles modelled here are from a time course assay of 
virus that has been thawed from frozen. A time course assay where a sample was subjected to a 
freeze-thaw cycle at 24h saw a similar steep decline in viral titer upon thawing (see Appendix A). 
These profiles may differ from those of fresh virus since samples that have undergone freeze-thaw 
cycles were subjected to more stresses that could cause accelerated viral inactivation, such as damage 
from ice crystal formation 55. Nevertheless, it is evident from the parameter estimates for the decay 
rate constants that some degradation pathways have been minimized in Lot C. It is possible that the 
components of Lot C are protecting the virus from specific pathways and this is seen in the reduction 
of the rate constant values. 
When the virus was in buffer with 0.1%-10% FBS, as the stability improved, the decay rate with 
respect to time appeared more linear instead of following first order or double decay trends. The rate 
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of decay in a zero order decay model does not depend on the concentration of the virus. The addition 
of FBS to the reference buffer caused the stability kinetics to deviate from a first-order reaction to a 
zero-order reaction. The modelling would benefit from more time points to resolve the shape of the 
curve further, especially in the first 24h, since this is typically where the decay is less linear. 
7.3 TEM imaging revealed a high prevalence of unenveloped virus and clumping of ACAM529  
TEM images of ACAM529 Lot A and Lot C were taken to identify differences between the lots and 
to visualize the structure of the virus. There was a high prevalence of naked capsids in both lots 
imaged. This could indicate uncoating of virus to be a cause for instability since naked capsids are not 
typically infectious 18. However, it is unclear whether the prevalence of naked capsids is due to the 
method of sample preparation or a true representation of the virus in liquid solution. The process of 
fixing the sample to the grid and staining may damage the viral envelope and it may also cause 
capsids to rupture, as broken capsids were also observed. Hansen and colleagues 17 quantified the 
ratio of enveloped HSV-2 and naked capsids on TEM grids and related it to virus titer. This 
quantification would be informative for ACAM529. It could reveal the cause for lower virus titers 
over time, whether it was uncoating due to damage to the viral envelope, particle aggregation, or 
some other mechanism. However, with the difficulties faced with imaging here, such as a poor ability 
to definitively identify enveloped virus, it would have been immensely challenging to produce such 
data. 
The inner structures of the virus were not as apparent as some reported in the literature 17,126,127. The 
capsid and DNA core in most enveloped virus identified were not highly visible. Optimizing the time 
for fixing or using an alternative fixative that can better preserve ultrastructure, such as 
glutaraldehyde 128, are areas that can be further explored to improve imaging.  
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TEM imaging also revealed the presence of clusters of both enveloped virus and naked capsids and 
this would affect the viral titer quantification. The plaque assay quantifies plaque-forming units 
(PFU) so an aggregation of viral particles would translate into only one PFU. Aggregates are 
indistinguishable from free-floating virus using this assay. Identifying the presence of aggregation 
would therefore be invaluable because excipients targeted for reducing aggregation could be used to 
improve virus titers. As an alternative to TEM imaging, clustering of enveloped virus and naked 
capsids could be confirmed using flow cytometry techniques. Flow cytometry has previously been 
used to study aggregation of baculovirus by tracking the change in particle size 129 and this technique 
may be transferrable to ACAM529. 
7.4 Culture media components as a promising source of stabilizing excipients 
In an effort to identify stabilizers for ACAM529, various culture media components were screened 
using the time course assay. 
7.4.1 FBS is an effective stabilizer for ACAM529 
ACAM529 Lot C was observed to have improved stability compared to the other lots and the 
question arose as to whether the significantly higher level of albumin seen in Lot C was contributing 
to the improved stability. The source of the albumin was unclear as it could be from FBS used 
commonly to supplement cell culture growth upstream, or a purified albumin could have been added, 
such as BSA, HSA, or rHSA. Though it is a complex mixture, the stabilization properties of FBS 
made it an excellent source to screen for stabilizing excipients and historically, serums and culture 
media have been used to stabilize viral preparations 116,117. Stability studies with 0.01%-10% FBS 
added to the reference buffer of ACAM529 Lot B saw significant improvements to the stability at 
27°C, with maximal stability achieved at 1% FBS. Replicate experiments with 1% or 10% FBS 
consistently showed significant protective effects for ACAM529 (Appendix G). This showed there 
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was substantial promise to further improve the stability of ACAM529 but the cause could be due to 
numerous factors. The addition of FBS to solutions not only introduced various compounds, such as 
proteins, vitamins, hormones, lipids, amino acids, and salts, but it also potentially altered other 
properties of the solution, such as the viscosity, osmolarity, and ionic strength. All or some of these 
properties may be contributing to the improved stability of ACAM529.  
7.4.2 Conditioned OptiPro SFM is a better stabilizer of ACAM529 compared to fresh media 
FBS has been used extensively for supporting cell growth, protecting cells from mechanical damage 
associated with culture mixing 118,119, cryopreservation, and even as a stabilizer for enveloped virus in 
liquid solution 100. However, there is an interest to replace serum use with defined mixtures due to 
high batch-to-batch variation, which can cause inconsistencies in fermentation processes 119, and due 
to the risk of transferring harmful pathogens since it is of animal origin. Serum-free media (SFM), 
with chemically defined recipes intended for culturing specific cell lines, have been developed for this 
purpose. OptiPro SFM is an animal origin-free chemically defined commercial medium optimized for 
culturing kidney derived cell lines as well as other attachment dependent cell lines, and it is used to 
culture the complementary Vero cells for ACAM529 production 12. In this work, it was observed that 
adding 10% fresh OptiPro SFM to the reference buffer did not significantly affect the stability of Lot 
B at 27°C, however the same amount of conditioned OptiPro SFM slightly improved the stability. 
Conditioned OptiPro SFM is a more complex solution containing cellular proteins and metabolites 
that may protect ACAM529 from degradation pathways. OptiPro SFM has an ultra low (< 10 µg/ml) 
protein content whereas it is unclear what the protein content of the conditioned media is. Since 
proteins have been used as stabilizers, it would be of interest to investigate the protein content of 
conditioned OptiPro SFM to see whether this could be contributing to ACAM529 stability.  
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7.4.3 The stabilizing effects of rHSA are dependent on temperature and concentration 
Albumin is the most abundant protein in FBS and it is a widely used stabilizer 97,98. This is mainly 
attributed to its amphiphilic properties as it has the capacity to bind to hydrophobic surfaces, which 
prevents aggregation and inactivation 57. Albumin is also able to bind to cellular membranes 130, 
providing protection against hydrodynamic forces experienced during cell culture 131. The FBS used 
in the present study contained 19 g/L albumin so the range of FBS concentrations tested that resulted 
in significantly improved ACAM529 stability corresponds to 1.9 g/L - 1.9 mg/L albumin. With the 
addition of 50% FBS to the buffer, which corresponds to 9.5 g/L, the virus stability remained 
unchanged. The addition of 0.5-5 g/L rHSA to the reference buffer, however, significantly reduced 
the stability of Lot B at 27°C in a concentration-dependent manner. Significant improvements at 27°C 
were only observed with 0.05 g/L rHSA. This was not expected since these levels are below what is 
present in Lot C. Furthermore, a study done by Carmo and colleagues 100 saw improved stability of 
enveloped viral vectors with the addition of 0.6 g/L-1 g/L rHSA in liquid solution. 
One difference between the albumin (rHSA) added to the buffer and the albumin found in Lot C and 
FBS is that the latter two undergo thermal stresses that could cause conformational changes in the 
protein. The albumin in Lot C is likely to experience thermal stress from freeze-thaw cycles as the 
virus samples used in these studies are thawed at 37°C from being frozen at -80°C. Similarly, FBS 
undergoes freeze-thaw cycles when taken from storage conditions at -80°C and in addition, it is 
commonly heat inactivated prior to culture use by heating at 56°C for approximately 0.5h. In this 
work, solutions of rHSA were either subjected to heat inactivation at 56°C for 0.5h; a freeze-thaw 
cycle by freezing at -80°C for 1h then quickly thawing at 37°C; a heat inactivation followed by a 
freeze-thaw cycle; or incubated on ice for the duration of all incubations. CD spectrometric analysis 
of rHSA did not reveal any permanent changes to protein secondary structure in all conditions tested. 
Albumin is known to undergo reversible conformation changes below 60°C 132, so it is possible that 
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any structural changes caused by the thermal stresses studied here may have been reversed when the 
temperature was equilibrated back to ambient conditions prior to analysis. Furthermore, far UV CD 
spectrometry only reveals information about the protein secondary structure. It would be of interest to 
see whether these thermal stresses cause changes to the tertiary structure because differences in 
protein folding could play a role in its viral stabilization properties. CD scans in the near UV region 
(250 – 350 nm) is commonly used to study protein tertiary structure. Though the information obtained 
from near UV scans is more qualitative (as it does not provide specific quantifiable tertiary structure 
characteristics), it is an adequate method for the comparative studies proposed here 105. 
At 2-4°C, adding 0.05-5 g/L rHSA improved the stability of Lot B. There is an interaction effect 
between rHSA and temperature that affects its stabilization properties for ACAM529. Wetzel and 
colleagues analyzed albumin using CD spectrometry and found reversible structural changes below 
60°C, whereas permanent changes were only observed between 65-80°C 132. Rezaei-Tavirani and 
colleagues also found reversible albumin conformational changes between 15-65°C through 
differential scanning calorimetry (DSC) analysis and 25-55°C as determined through far UV CD 
spectrometry 114. Again, permanent changes associated with protein unfolding were only observed 
above 65°C. It is possible that at lower temperatures, rHSA assumes a more favorable conformation 
to stabilize ACAM529. CD spectrometry studies of rHSA at temperatures between 4-27°C would be 
beneficial to study these conformation changes. Scans in the far UV region would uncover any 
secondary structure differences and scans in the near UV region would show any changes to tertiary 
structure 105,106.  
7.4.4 Cholesterol lipid concentrate solution destabilizes ACAM529 
Cholesterol lipid concentrate (CLC) is an animal- and protein- free chemically defined lipid solution 
used for culturing lipid-dependent cell lines 120,121. Sanofi Pasteur reportedly used it in the production 
of ACAM529 12 and they hold a patent (US 20110201087 A1133) for its use in the production of alpha 
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herpes virus, including ACAM529. They found an improved virus yield with the addition of CLC to 
the culture media. However, this work showed that the addition of 0.1-1x CLC to the reference buffer 
saw significant decrease in the stability of Lot B at 27°C, especially in the first 24h. Cholesterol is 
necessary for viral envelope synthesis so it is unsurprising that culture supplementation with 
cholesterol aids in viral production for numerous enveloped virus such as herpes virus 94 and 
lentivirus 93. Lentivirus stability in liquid solution has also been improved with the addition of 
lipoproteins 100. Another application for cholesterol is in the production of liposomes as it protects the 
bilayers from mechanical breakage 95. However, due to the nonpolar nature of cholesterol, increased 
levels were shown to decrease the overall surface charge and ion-lipid interactions in synthetic 
membranes 96. This reduction in ion-lipid interaction decreases the strength of the membrane as 
mentioned above 61. This could explain the negative impact that CLC had on ACAM529 stability. 
The increased concentrations of cholesterol and lipids may be destabilizing the viral membrane, 
leading to inactivation. Therefore, it is important to minimize the amount of CLC present after 
harvesting the virus from the culture. Buffer exchange steps, such as tangential flow filtration, which 
essentially dilute the solution into a new buffer, should be used to reduce the levels of CLC. 
7.4.5 Pluronic F68 is an effective stabilizer for ACAM529 
Pluronic F68 (PF68) is a non-ionic surfactant that is widely used as a cell culture shear protectant at a 
concentration of 0.1%. It associates with cellular membranes and this is thought to provide stability to 
the membrane and improve the health of the culture 89,91,92. In this work, PF68 was found to 
significantly stabilize ACAM529 at concentrations between 0.01%-0.1%, with maximal stability 
achieved using 0.1% PF68. Replicate experiments with 0.05%-0.1% PF68 were consistent with these 
results (Appendix G). However at 1% PF68, which is above the CMC for PF68 (0.4%), the virus was 
destabilized. Povidone was another culture shear protectant studied however it was not as effective as 
PF68 (see Appendix H). At concentrations typically used during cell culture (0.1% (w/v)), it did not 
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significantly affect virus stability over 120h. It also did not have any interaction effect with 2 g/L 
rHSA in its stabilization properties. At concentrations of 1% and 10%, povidone had a significantly 
negative impact on viral stability. 
Though PF68 did not stabilize ACAM529 to the same extent as FBS, it is a promising excipient 
because it has been used in FDA approved drugs. It has been included as an inactive ingredient in 
FDA approved intravenous drugs up to 0.6% (w/v) and subcutaneous drugs up to 0.2% (w/v) 
(https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm, accessed 03/27/2018). Further 
optimization of the concentration between 0.1% and 0.4% would be beneficial. Furthermore, Mundle 
and colleagues 12 noted that shear stress contributed significantly to the step yield of ACAM529 
during purification processes, so not only would PF68 aid in product stability, but its shear protectant 
properties could further improve recovery of infectious virus during purification processes. 
7.5 Screening of excipients is an important aspect of buffer optimization 
Several other buffer conditions and excipients were explored for their stabilization properties for 
ACAM529 and they were chosen based on their past success with protecting enveloped viruses or 
proteins. Each biological product is different and conditions that are optimal for one may not 
necessarily be the case for another. Therefore it is important to test the conditions with the product of 
interest. 
7.5.1 Low pH buffer condition increases ACAM529 infectivity but decreases stability  
Physiological pH, approximately 7.4, is a condition in which many biological products are most 
stable. During the production and purification process, the virus may experience changes in pH. For 
example, the virus is often frozen at certain stages of the purification process but it has been reported 
that uneven freezing of a sample has the potential to create pockets of concentrated protons, leading 
to microenvironments with low pH 55. HSV-1 was shown to have higher rates of association with 
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membranes at low pH (<5.3) in the presence of the HVEM receptor on cell membranes 37,134.The 
lower pH is thought to act as a co-activation signal for HSV membrane fusion and entry. Although 
beneficial for infection, low pH environments may not necessarily be favourable for longer-term 
stability 135. 
The effect of the pH of the environment on ACAM529 infectivity and stability was studied. Low pH, 
although beneficial for infection, resulted in accelerated deactivation of Lot A at room temperature 
when compared to pH 6 and pH 7 conditions. Studies conducted by Lancz and Sample also saw 
decreased HSV stability below pH 6 and above pH 8 after 90 minutes incubation at 37°C 135. The low 
pH is likely to have caused damage to the viral particles, especially the glycoproteins necessary for 
cell entry. It is hypothesized that gB, a highly conserved glycoprotein necessary for viral entry, along 
with gH/gL, undergo conformational changes at lower pH (~6.0-5.0), making it more hydrophobic 136. 
This is necessary for viral entry however it was observed that prolonged exposure to an acidic 
environment in the absence of a cell membrane caused HSV to quickly lose infectivity due to 
irreversible conformational changes 134. In general, the overall charge of a protein is pH-dependent 
and this affects not only the structure of the protein but also the enzymatic activity 13. Here it was 
observed that ACAM529 is not significantly sensitive to pH shifts between pH 6-7 but effort should 
be put into controlling the environment to prevent exposure to increased acidic conditions. 
7.5.2 Trehalose, L-arginine, and NEAA do not have a significant effect on ACAM529 stability 
Disaccharides are commonly used in vaccine formulations due to the role they play in preferential 
exclusion in liquid solution 65 and for their capacity to remain amorphous during freeze-drying, where 
they are thought to form a glass around the product 55. Sucrose is widely used in vaccine formulations 
13,55,74 and it is used in the reference buffer for ACAM529. Another increasingly popular disaccharide 
used in formulation is trehalose 55,66,67,69,70,72,76,77 and it has been shown to have superior properties 
over sucrose. It has a higher viscosity and a larger hydrated volume, increasing the effect of 
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preferential exclusion and requiring 3x less molecules than sucrose 69. In the current study, 
concentrations of 10%-30% trehalose offered the same level of stability as 10% sucrose to ACAM529 
at 27°C. It did not appear as though trehalose was a superior stabilizer over sucrose for ACAM529 in 
liquid solution. The use of trehalose in lyophilized products is also common and the fact that it does 
not hydrolyze into reducing monosaccharides at low pH, unlike sucrose 73, is relevant. Product frozen 
at different stages during the manufacturing process can lead to elevated localized proton 
concentration, thus promoting the hydrolysis of sucrose into the reducing sugars fructose and glucose. 
Monosaccharides act as reducing agents in solution and can undergo the Maillard reaction with free 
amino groups on proteins, altering charge, conformation, and degradation rates 71. Therefore it would 
be of interest to study the stabilizing effects of trehalose compared to sucrose through freeze-thaw 
experiments. 
Amino acids have been implicated in biological product stabilization due to their buffering 
capabilities 58, antioxidant properties 85,86, and generally favourable interactions with biochemical 
compounds 76,81,123. The reference buffer in this work contains both histidine and glutamate. Histidine 
has been shown to stabilize antibodies through non-covalent interactions 56 and be an effective 
oxygen radical scavenger 85. L-arginine has become an amino acid of interest as it has been used 
extensively as an excipient to stabilize proteins 80,82 and to discourage protein aggregation 83,124. 
Arginine has previously been shown to have a significant impact on deactivating HSV-1 below pH 4 
137. In this work, it was found that the addition of 0.01 M-0.1 M L-arginine to the reference buffer did 
not significantly affect the stability of ACAM529.  
Eagle’s minimum essential medium (MEM) non-essential amino acid solution (NEAA) is another 
amino acid source previously shown to have stabilization properties. The 1x NEAA solution contains 
10 mM each of glycine, L-alanine, L-asparagine, L-aspartic acid, L-glutamic acid, L-proline, and L-
serine. It has been used in culture of hybridoma cells and it was shown to improve membrane stability 
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as well as improve antibody production 123. However, when added to ACAM529 reference buffer at 
0.1-1x concentrations, it did not have any significant effect on the stability of the virus at 27°C. The 
study done on hybridoma cultures could have seen improved membrane stability due to improved 
metabolic activity as increased antibody production was also observed with NEAA 123. If this were 
the main mode of action for NEAA, it would be a good indicator as to why it did not induce changes 
to ACAM529 stability.  
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Chapter 8  
Conclusions 
The purpose of this research was to study the stability of ACAM529 vaccine candidate and identify 
excipients that would further improve the stabilization buffer used for the purification of the virus. 
The objectives outlined in Chapter 1 were to first study the stability of different lots of virus that vary 
in the production processes, then screen for potential stabilizing excipients in complex and defined 
solutions used during cell culture, and finally to screen other common stabilizers used for lipid- and 
protein-based biologicals.  
The first objective was explored in Chapter 4. Virus produced using different production and 
purification procedures have varying titers, albumin content, and stability. Lot C had the highest titer, 
highest albumin content, and was the most stable of the three lots studied. Virus stability increased 
with decreased temperatures and the stability profiles followed a first order exponential decay trend at 
27°C and 37°C. At lower temperatures, the stability more closely followed a double decay model, 
which suggests the presence of two subpopulations of virus, each undergoing different rates of decay. 
The second and third objectives were explored in Chapter 5 and Chapter 6, respectively. The results 
of this work have identified various compounds and conditions that improve viral stability when 
added to the liquid stabilization buffer and conversely, compounds and conditions that accelerated the 
deactivation of the virus. There were also several additives that the virus was found to be tolerant to 
and did not significantly affect the stability.  
FBS, PF68, and rHSA in small concentrations or at reduced temperature improve the stability of 
ACAM529. Minimal log loss in titer at 27°C was achieved with 1% (v/v) FBS or 0.1% PF68. The 
addition of small amounts (0.05 g/L) rHSA improves stability at 27°C and the addition of 0.05-5 g/L 
rHSA improves stability at 2-4°C in a concentration-independent manner. Though PF68 was not as 
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effective as FBS, it is a promising excipient to use for ACAM529, especially as it is present in FDA 
approved intravenous and subcutaneous drugs. 
ACAM529 stability decreases with higher concentrations of rHSA at ambient conditions, CLC, high 
concentrations of PF68, and acidic pH. Significantly high log loss in titer at 27°C was observed with 
the addition of 0.5-5 g/L rHSA, 0.1-1x CLC, and 1% (w/v) PF68. Altering the buffer from pH 7 to pH 
5, though significantly increased the initial infectivity of the virus, caused destabilization over 120h at 
room temperature. 
Lastly, 50% FBS, 10% OptiPro SFM, buffer pH 6-7, 10-30% trehalose pH 6, 0.01 M-0.1 M L-
arginine and the resultant 40-220 mM increase in Cl- ions, and 0.1x-1x NEAA do not alter the 
stability of ACAM529 were. 
The work presented here has made a substantial contribution towards improving the stability of 
ACAM529 in liquid solution. Several beneficial compounds have been identified and further research 
can be directed towards studying and optimizing these compounds to ensure optimal stability with 





Moving forward with the stabilization buffer for ACAM529, several recommendations can be made. 
The highest level of stability near ambient conditions was observed with 1% FBS. It is of great 
interest to identify the specific stabilizers in FBS since it is a complex mixture with high batch-to-
batch variability. In addition, its presence should be minimized in the final product due to its animal 
origin. Fractionation studies using ammonium sulfate precipitation and chromatography techniques 
138,139 would help identify active fractions of FBS. Also, delipidation of FBS 100 would narrow down 
whether the lipids are important for stabilization. 
The apparent interaction effect between rHSA and temperature is also of interest to explore further 
because at low temperatures, rHSA significantly improved the stability of the virus. Near and far UV 
CD spectrometry at temperatures between 4-27°C can be used to study whether there are any changes 
to rHSA tertiary and secondary structure, respectively. In this work, adding rHSA to the reference 
buffer at concentrations of 0.5-5 g/L at 27°C reduced the stability of the virus however, virus lots 
with higher levels of albumin carried over from culturing after purification were more stable. One of 
the major roles of albumin natively is to bind and transport materials through the circulatory system 
and it has been well documented to bind various types of compounds, primarily fatty acids, but also 
heme and many pharmaceutical drugs 101. The binding of ligands to albumin may induce 
conformational changes to the protein 101,102, potentially altering the protein’s viral stabilization 
properties. Small ligands that bind to albumin have a higher likelihood of being retained in the 
various filtration steps during purification. One study found that different sources of albumin, 
whether they were native BSA and HSA or rHSA produced in rice or yeast, had variable levels of 
fatty acid content 140. The number of fatty acids bound to albumin and the chain length of each 
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molecule was thought to affect the thermal stability because the different types of albumin had 
variable thermal transition temperatures. It would be of interest to determine the fatty acid content of 
the rHSA used in this work and perform binding studies with rHSA and various fatty acids to identify 
whether they can stabilize a more favourable rHSA conformation.  
This work identified PF68 as a promising excipient for ACAM529 and moving forward, the optimal 
concentration, between 0.1%-0.4% (w/v) should be determined. It would also be beneficial to obtain a 
full stability profile at different temperatures to model the stability and compare it to the stability 
curves with FBS in the buffer. This could elucidate how similar the mechanisms of stabilization are 
between the solutions.  
Investigating the mechanism by which PF68 is stabilizing the virus would allow for a more directed 
approach to further improve the stability. To study whether PF68 is affecting the ACAM529 
membrane stability, various aspects of the membrane in the presence of PF68 can be studied. The 
effects of PF68 on the prevalence of intact envelopes could be analyzed using TEM imaging. In 
addition, laurdan dye, which incorporates into lipid bilayers, can be used to assess differences in 
membrane fluidity 79. The emission spectrum of the dye is sensitive to the level of membrane 
hydration and thus changes to membrane fluidity in the presence of PF68 can be analyzed using 
fluorescence spectrometry. ACAM529 has also been observed to form aggregates when viewed 
through TEM. Aggregation would cause an apparent decrease in titer when using the plaque assay. 
The effect of PF68 on ACAM529 aggregation could be studied qualitatively using TEM imaging. 
More quantitative approaches to study aggregation include flow cytometry 129 or optical density 
measurements at 360 nm 79. 
Since the primary objective of this work was to identify potential excipients, there was little to no 
agitation applied to the assayed samples. However, it should be noted that during purification 
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processes, the virus is likely to experience various physical and chemical stresses from steps such as 
tangential flow filtration and benzonase treatment for DNA clarification 12. Therefore, the next step in 
developing the stabilization buffer, once the concentrations of PF68 have been optimized, is to test 
whether the protective effects are translatable through the finalized purification protocol.  
Another aspect of the purification protocol is that samples are often frozen for storage. Therefore, it 
would be of interest to study the effects of the stabilizers identified here in protecting the virus 
through a freeze-thaw cycle. Freezing could cause pockets of low pH environments 55. Trehalose is 
not known to hydrolyze into reducing sugars like sucrose at low pH, so it has the potential to be a 
better choice for disaccharide over sucrose for protection during freeze-thaw cycles. In this study, 
trehalose was just as effective a stabilizer as sucrose in liquid formulations but it would be interesting 
to see whether this would hold true after a freeze-thaw step. Trehalose is significantly more expensive 
than sucrose (ten times the amount compared to sucrose for cell culture-grade material through 
Sigma-Aldrich) so it would be important to determine whether it aids in recovering a significant level 
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Time course assay design  
Purpose 
The following appendix describes the considerations taken into account when designing the time 
course assay for ACAM529 stability studies. A number of preliminary experiments were also 
conducted and are presented here. 
A.1 General protocol considerations 
The purpose of the work was to improve a buffer that would stabilize ACAM529 during purification 
procedures. A time course assay tracking viral titer over time was determined to be an adequate 
method for testing various stability buffers and conditions. Decisions about the aspects of the time 
course assay were made by considering the circumstances of product purification 12:  
• Purification procedures typically take 1-3 days but in order to allow for a complete profile of 
the viral stability, here the time courses were run for 5 days (120 hours).  
• Most steps of the purification, including clarification, buffer exchange, and filtration, are 
done at ambient temperatures so time course assays were carried out at room temperature, 
25°C, or 27°C.  
• HSV-2 is known to be photosensitive 141 so all samples were covered in foil for the duration 
of the experiments. 
• Since the primary objective is to identify potential excipients, there was little to no agitation 
applied to the assayed samples. However, it should be noted that during purification 
processes, the virus is likely to experience various physical and chemical stresses from steps 




A.2 Effect of viral dilution into test buffers 
A method for suspending the virus in the buffer of interest was needed. To minimize processing of 
the virus and risk losing viral activity, a simple method of diluting the virus into the buffer was 
proposed. To determine the effect of diluting the virus on its stability, a time course assay was 
conducted. Frozen purified virus stock Lot A was quickly thawed at 37°C and was either left 
undiluted or diluted 1/10 or 1/100 into freshly prepared reference buffer. Samples were incubated at 
room temperature and plaque assays were performed in triplicate immediately upon dilution (0h), and 
at 2h, 10h, 24h, 48h, 72h, 97h, and 121h as described in Chapter 3. Results indicated that the virus 
diluted 1/100 was not as stable as the undiluted or the 1/10 diluted virus after 24h (Figure A.1A) 
however the overall log loss in titer for each of the different dilutions showed no significant 
difference (α=0.05) (Figure A.1B). Diluting the virus 1/100 was therefore concluded to be an 
adequate method for suspending the virus, as it is a simple process. If similar discrepancies from 
diluting the virus arise in future time course assays similar to the ones observed here, it would show a 
conservative underestimate of the stability of the virus and avoid inflating the stability of the virus.  
 
 





A.3 Effects of a freeze-thaw cycle on ACAM529 
For time course assays requiring more frequent sampling times, it was not possible to perform plaque 
assays immediately. For this purpose, it was often necessary to freeze samples taken during the time 
course and thaw them at a later date to perform the plaque assay.  To determine whether this would 
affect the observed titer, a frozen aliquot of ACAM529 Lot A, Lot B, and Lot C was quickly thawed 
at 37°C and a sample was diluted in triplicate in the reference buffer, then immediately titered using 
the plaque assay as described in Chapter 3. The remainder of the aliquot was subjected to a freeze-
thaw cycle by freezing at -80°C for approximately 24h, then thawing at 37°C for a plaque assay. 
Results showed no significant difference in the viral titer before and after the freeze-thaw cycle for all 
lots (Figure A.2) at a significance level of α = 0.05.  
To determine the effect of a freeze-thaw cycle on the stability of ACAM529 over a longer period of 
time a time course study with a freeze-thaw cycle was conducted with Lot C. Frozen virus was 
quickly thawed at 37°C and diluted 1/100 in the reference buffer. Triplicate samples were taken for 
tittering using the plaque assay as described in Chapter 3 at 0h, 2h, 8h, 24h, 48h 50h, 56h, 72h, 96h, 
and 120h. At 24h, a sample was also taken and frozen at -80°C for 24h, then quickly thawed at 37°C. 
Triplicate samples were titered in a similar manner at the same time points as the original sample. The 
stability profile is shown in Figure A.3 and results showed that upon thawing the sample that 
underwent an addition freeze-thaw cycle, the titer was similar to the titer before the cycle (compare 
24h data point to 48h data point for the freeze-thaw sample). This was consistent with results shown 
in Figure A.2. However, a dramatic decrease in titer was observed in the first 2h after the freeze-thaw 
cycle. The cycle had a negative effect on the stability of the virus and it was most sensitive to 
degradation 2h after thawing. 
Since the titer of the sample before and immediately after a freeze-thaw cycle were very similar, it 
was concluded that freezing samples prior to titering was an appropriate method for handling a large 
number of samples. However, it should be assured the plaque assays are preformed immediately upon 
thawing the frozen samples, as the effect on longer-term viral stability is significant. Furthermore, all 














A.4 Effects of complementary Vero cell age on ACAM529 titer 
Plaque assays were chosen as the method for tracking ACAM529 activity however a disadvantage of 
the assay is that it indirectly quantifies the viral particles by counting the effect it has on the 
monolayer of complementary Vero cells. To determine the working complementary Vero cell passage 
number range for the time course plaque assays, an experiment studying cell age was performed. A 
vial of ACAM529 Lot C was aliquoted into 7 cryovials, then frozen at -80°C. A plaque assay was 
performed at the beginning of each week during an eight-week culture of complementary Vero cells 
using one of the ACAM529 aliquots to infect the cells in triplicate as described in Chapter 3. Viral 
titers in PFU/ml were reported at the specified culture passage number (2-3 passages are typically 
performed each week) and the results are presented in Figure A.4. Though there was variability 
among the titers at different passage numbers, there was no significant difference between the 
reported values so it was concluded that cells should be used under passage 25. 
 
 





Optimization of conditions for CD spectrometry 
B.1 Purpose 
Circular dichroism (CD) spectrometry was used to study the secondary and tertiary structure of rHSA. 
This appendix details the steps taken to determine the optimal choice of buffer and to optimize the 
concentrations of rHSA to be used in the analysis.  
B.2 Experimental protocol 
B.2.1 Buffer optimization 
Four buffers used in the literature for CD analysis of albumin were tested here to look for minimal 
signal disruption of the polarized light and for its ability to maintain secondary structure of albumin. 
The buffers tested were “10 mM Phosphate” (10 mM sodium phosphate (Sigma-Aldrich), pH 7) 114, 
“25 mM Phosphate” (25 mM sodium phosphate, 150 mM NaCl (Sigma-Aldrich), pH 7.4) 99, “5 mM 
Phosphate” (5 mM sodium phosphate, pH 7.4) 142, and “100 mM Tris” (100 mM Tris-HCl (Bio-Rad), 
100 mM NaCl, pH 7.4) 143. Buffers were prepared the same day and 2 g/L rHSA (Cellastim, Invitria) 
was dissolved in each buffer and incubated on ice prior to CD analysis. CD spectra were obtained on 
a Jasco J-715 CD spectrometer with the accompanying Spectra Manager software. Scans were done at 
room temperature in quartz SUPRASIL cuvettes (Hellma Analytics, Mullheim, Germany) with 0.1 
cm path length for the far UV region (260 nm – 170 nm). Samples containing albumin were diluted 
with the appropriate buffer immediately before loading into the cuvette to a concentration of 0.5 g/L 
for scans 132. The response time used was 0.125 s with a data pitch of 0.5 nm and a scan speed of 100 
nm/min. A total of 10 accumulations were acquired for each run and cuvettes were rinsed thoroughly 
with DI water between runs. Buffer background scans (without albumin) were obtained to establish 
the baseline. All scans were smoothed using the Spectra Manager software “Means-Movement” 
method and the baseline spectra were subtracted from the albumin spectra. Molar ellipticity was 
calculated as described in Chapter 3. Data was visualized by plotting the calculated molar ellipticity 




B.2.2 Concentration of rHSA optimization in the far UV region 
The optimal concentration of rHSA for far UV CD spectroscopic analysis was determined. A 2 g/L 
rHSA sample in 10 mM Phosphate buffer (pH 7) was prepared the same day and incubated on ice 
prior to dilution and/or analysis. The sample was diluted using 10 mM Phosphate buffer to the 
following concentrations: 2 g/L (undiluted), 1 g/L, 0.5 g/L, 0.25 g/L, 0.1 g/L, and 0.05 g/L and 
analysis was done as mentioned above. Secondary structure composition was determined using 
DichroWeb software with the K2D method 144,145. 
B.3 Results and conclusions 
B.3.1 Buffer optimization 
An appropriate buffer for rHSA analysis using CD spectrometry will have minimal absorbance of the 
circularly polarized while also stabilizing the structure of the protein. Here, four buffers previously 
reported in literature for CD analysis of albumin were tested and the results are presented in Figure 
B.1. The high-tension voltage represents the amount of voltage applied to the sample to gain a signal. 
With samples that absorb a lot of light, especially at wavelengths below 200 nm, the voltage must be 
increased but once the value plateaus, the CD signal is no longer reliable in this region. The buffers 
that contained sodium chloride (25 mM Phosphate and 100 mM Tris) saw a high-tension voltage 
plateau at higher wavelengths than the buffers without (10 mM Phosphate and 5 mM Phosphate). 
This would imply that the buffers with sodium chloride absorb more light than those without in that 
region. This would also cause the reduction in negative CD signal at 208 nm seen with the sodium 
chloride-containing buffers. The buffers without sodium chloride produced similar CD spectra for 
rHSA. The 10 mM Phosphate buffer was chosen over the 5 mM Phosphate buffer for further 




Figure B.1 Buffer optimization for CD spectrometry analysis of rHSA 
The high-tension voltage readings (top plot) and calculated molar ellipticities (bottom plot) of CD 





B.3.2 Far UV region rHSA concentration optimization 
The secondary structure of rHSA is known to be composed predominantly of alpha helices and a CD 
spectrum reflecting this is ideal. Alpha helical structure causes strong negative peaks at 222 nm and 
208 nm, and a strong positive peak at 195 nm. In order to determine the optimal concentration of 
rHSA to use for analysis, solutions containing 2 g/L, 1 g/L, 0.5 g/L, 0.25 g/L, 0.1 g/L, and 0.05 g/L 
rHSA in 10 mM Phosphate buffer were analyzed in the far UV region (170 nm-260 nm) using CD 
spectrometry and the results are presented in Figure B.2. From the high-tension voltage values, it is 
evident that the higher concentrations of rHSA absorb more light at lower wavelengths and cause the 
voltage output to plateau at wavelengths ideal for secondary structure analysis. Though the higher 
concentration of rHSA results in stronger CD signals, the plateau in the high-tension voltage reduces 
the information that can be gained from the spectra. The negative peak at 208 nm is only observed at 
concentrations of 0.5 g/L and below, and the expected positive peak at 195 nm is only observed at 
concentrations of 0.25 g/L and below. After normalizing the spectra for protein concentration, it is 
evident that the signals from the 0.1 g/L and 0.05 g/L rHSA samples were similar, with the exception 
of the reduction in peak height at 195 nm for the former. The secondary structure composition was 
estimated using DichroWeb software with the K2D method (Table B.1) and the plots generated by the 
software showing the fit are displayed in Figure B.3. The software estimation for the alpha helical 
content of 0.1 g/L and 0.05 g/L rHSA (60% and 63%, respectively) fit best and was closest to 
literature values for Cellastim (66.7%-64.7%) 142. For further experiments in the far UV region, a 
concentration of 0.1 g/L rHSA was chosen as it has the optimal signal quality. 
 
Table B.1 Secondary structure predictions of rHSA based on CD Spectra at various rHSA 
concentrations using the K2D method on DichroWeb. 





2 g/L 5 47 48 
1 g/L 32 12 55 
0.5 g/L 45 23 31 
0.25 g/L 59 7 33 
0.1 g/L 60 7 32 






Figure B.2 Optimization of rHSA concentration for far UV CD spectroscopic analysis 
The high-tension voltage readings (top plot), smoothed CD values in mdeg (middle plot), and 
calculated molar ellipticities (bottom plot) for CD scans performed in the far UV region of various 
concentrations of rHSA in 10 mM Phosphate buffer.  
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Figure B.3 Fitting CD spectra of various concentrations of rHSA to estimate secondary 
structure. 
DichroWeb’s K2D method was used to estimate the secondary structure of rHSA using CD spectra of 
rHSA at different concentrations. The plots were generated on DichroWeb and show the goodness of 
fit for rHSA at a concentration of 2 g/L (A), 1 g/L (B), 0.5 g/L (C), 0.25 g/L (D), 0.1 g/L (E), and 




Analyzing protein content of ACAM529 
Various dilutions of Lot A and Lot C were run on SDS-PAGE as described in Chapter 3 to analyse 
the protein content (Figure C.1). Table C.1 summarizes the size and molar abundance of viral proteins 




Figure C.1 SDS-PAGE analysis of ACAM529 Lot A and Lot C. 
Dilutions of Lot A and Lot B (indicated above each lane) were run on SDS-PAGE, with rHSA used 
as a protein concentration standard. PageRuler Prestained (first lane) and Unstained (last lane) Protein 




Table C.1 Composition of extracellular HSV-1 virion particles 31. 






UL36/Large tegument Tegument 3164 335.9 5-10% 
UL19/VP5 or ICP5 Capsid 1374 149.1 >10% 
RS1/ICP4 Tegument 1298 132.8 1-4% 
UL37/ICP32 Tegument 1123 120.6 1-4% 
UL27/gB Envelope 904 100.3 5-10% 
UL22/gH Envelope 838 90.4 1-4% 
RL2/ICP0 Tegument 776 78.5 1-4% 
UL46/VP11/12 Tegument 718 78.2 1-4% 
UL17 Capsid 703 74.6 1-4% 
UL6 Capsid 676 74.1 <1% 
UL47/VP13/14 Tegument 693 73.8 >10% 
UL25 Capsid 580 62.7 1-4% 
US8/gE Envelope 550 59.1 1-4% 
UL21 Tegument 535 57.6 1-4% 
UL13 Tegument 518 57.2 <1% 
UL44/gC Envelope 511 55 1-4% 
UL41/vhs Tegument 489 54.9 1-4% 
UL48/VP16/ICP25 Tegument 490 54.3 1-4% 
US3 Tegument 481 52.8 <1% 
UL10/gM Envelope 473 51.4 <1% 
UL38/VP19C Capsid 465 50.3 <1% 
US6/gD Envelope 394 43.3 1-4% 
US7/gI Envelope 390 41.4 <1% 
UL23/TK Tegument 376 41 <1% 
UL16 Tegument 373 40.4 <1% 
UL50/dUTPase Tegument 371 39.1 1-4% 
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UL18/VP23 Capsid 318 34.3 5-10% 
US10 Tegument 312 34.1 <1% 
UL7 Tegument 296 33.1 <1% 
US2 Tegument 291 32.5 <1% 
UL49/VP22 Tegument 301 32.3 5-10% 
UL26/VP24 Capsid 247 26.6 1-4% 
RL1/ICP34.5 Tegument 248 26.2 <1% 
UL51 Tegument 244 25.5 <1% 
US4/gG Envelope 238 25.2 <1% 
UL1/gL Envelope 224 24.9 <1% 
UL20 (+) Envelope 222 24.2 <1% 
UL14 Tegument 219 23.9 <1% 
UL56 Envelope 197 21.2 <1% 
UL55 Tegument 186 20.5 <1% 
UL45 Envelope 172 18.2 1-4% 
UL35/VP26 Capsid 112 12.1 1-4% 
UL11 Tegument 96 10.5 <1% 
US9 Envelope 90 10 <1% 




Comparing the stability of different lots of ACAM529 at various 
temperatures 
See section 4.2.3. The data in Figure D.1 below are duplicates of the data found in Figure 4.3, with 
the exception of the data for ACAM529 Lot B in Figure D.1A and D.1B, which were not presented in 
Figure 4.3. Here, the data was arranged to better show how the stability of each lot of ACAM529 
compared to one another at various temperatures. 
 
Figure D.1 Stability of different lots of ACAM529 at various temperatures. 
Lot A and Lot B were diluted into the reference buffer and incubated at 2-4°C or 25°C. Viral stability 
(A) and the total log loss in titer was determined (B). In a second experiment, Lot B and Lot C were 
diluted into the reference buffer and incubated at 2-4°C, 27°C or 37°C. Viral stability (C) and the 
total log loss in titer was determined (D). A significant deviation (α = 0.05) from Lot B at the same 





Characterized FBS of Canadian origin 
Table E.1 reproduces the certificate of analysis and biochemical analysis performed by HyClone on 
characterized FBS of Canadian origin (www.gelifesciences.com/en/us/support/quality/certificates, 
Catalogue: SH30396, Lot: AAF204951). To confirm the levels of albumin in the FBS, SDS-PAGE 
was performed as described in Chapter 3 (Figure E.1). The albumin content in FBS as determined 
through SDS-PAGE indeed agreed with HyClone’s certificate of analysis, which reports an albumin 
concentration of 19 g/L. 
Table E.1 Certificate of analysis and biochemical assays for FBS 
Test Lot Value Unit 
Endotoxin <0.125 EU/ml 
Hemoglobin 3 mg/dL 
Proteins/Other   
Albumin 1.9 g/dL 
Alkaline Phosphatase 283 U/L 
Blood Urea Nitrogen 13 mg/dL 
Creatinine 2.94 mg/dL 
Gamma Globulin 2.8 % tp 
Glucose 84 mg/dL 
Glutamix Oxaloacetic Transaminase 17 U/L 
Glutamic Pyruvic Transaminase 8 U/L 
IgG – Nephelometer 0.104 mg/mL 
Lactate Dehydrogenase 582 U/L 
Osmolality 271 mOsm/kg 
pH 7.10  
Total Bilirubin 0.1 mg/dL 
Total Protein 3.8 g/dL 
Trace Metals/Iron   
Calcium 14.6 mg/dL 
Chloride 104 mmol/L 
Inorganic Phosphorus 10.7 mg/dL 
Iron 155 µg/dL 
Percent Saturation (Iron) 57 % 
Potassium >10.0 mmol/L 
Sodium 143 mmol/L 







Figure E.1 SDS-PAGE analysis of the albumin content in FBS. 
Dilutions of FBS lot AAF204951 were run on SDS-PAGE and the gel is labelled with the expected 
concentrations of BSA (~66 kDa) in each dilution of FBS (calculated using values reported in the 
certificate of analysis). The reference standards used were rHSA and BSA. PageRuler Prestained 
(first lane) and Unstained (second and last lanes) Protein Ladder were used and protein sizes are 




Supplementary data from model fitting in R 
F.1 Modelling ACAM529 stability in the reference buffer with or without FBS: 
F.1.1 Summary of parameter estimates 
Table F.1 Estimates for V0 in the first order decay model: V(t) = Vo e(-kt) 
Buffer V0 Standard error t value Pr (>|t|) 
Reference buffer 1.70 x 105 5.73 x 103 29.73 0.00113** 
+ 0.01% FBS 1.81 x 105 6.71 x 103 26.985 0.00137** 
+ 0.1% FBS 2.03 x 105 0.958 x 103 212.01 2.22 x 10-5 *** 
+ 1% FBS 2.05 x 105 5.01 x 103 40.86 0.000599*** 
+ 10% FBS 1.98 x 105 7.66 x 103 25.921 0.00148** 
+ 50% FBS 1.94 x 105 15.4 x 104 12.608 0.00623** 
Significance codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Table F.2 Estimates for k in the first order decay model: V(t) = Vo e(-kt) 
Buffer k Standard error t value Pr (>|t|) 
Reference buffer 12.7 x 10-3 1.04 x 10-3 12.19 0.00667** 
+ 0.01% FBS 8.97 x 10-3 8.99 x 10-4 9.986 0.00988** 
+ 0.1% FBS 5.68 x 10-3 9.22 x 10-5 61.65 0.000263*** 
+ 1% FBS 4.30 x 10-3 4.38 x 10-4 9.81 0.010232* 
+ 10% FBS 5.25 x 10-3 7.33 x 10-4 7.154 0.01899* 
+ 50% FBS 9.64 x 10-3 2.01 x 10-3 4.795 0.04085* 
Significance codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Table F.3 Parameter estimates for the zero order decay model: V(t) = Vo - kt 
Buffer V0 k R2 Adjusted R2 
Reference buffer 1.58 x 105 1048.0 0.9203 0.8804 
+ 0.01% FBS 1.73 x 105 963.1 0.946 0.919 
+ 0.1% FBS 2.00 x 105 834.04 0.9948 0.9922 
+ 1% FBS 2.03 x 105 698.08 0.996 0.994 
+ 10% FBS 1.97 x 105 791.93 0.9914 0.987 












> # Loading data----- 
> data<- read.csv('compiledstudies.csv', header=TRUE) 
>  
> #Axis scales---- 
> fancy_scientific <- function(l) { 
+   # turn in to character string in scientific notation 
+   l <- format(l, scientific = TRUE) 
+   # quote the part before the exponent to keep all the digits 
+   l <- gsub("^(.*)e", "'\\1'e", l) 
+   # remove + after exponent, if exists. E.g.: (3x10^+2 -> 3x10^2) 
+   l <- gsub("e\\+","e",l) 
+   # convert 1x10^ or 1.000x10^ -> 10^ 
+   l <- gsub("\\'1[\\.0]*\\'\\%\\*\\%", "", l)  
+   # turn the 'e+' into plotmath format 
+   l <- gsub("e", "%*%10^", l) 
+   # return this as an expression 
+   parse(text=l) 
+ } 
> #Study8 ([FBS])------------------------------------------------------ 
> #Plaque count range setting 
> plq8<-data[data$EXP==8 & data$PlaqueCount>19 & data$PlaqueCount < 235,] 
>  
> #get averages  
> grouped8<- plq8%>% 
+   group_by(Time, Name) %>% 
+   mutate(avg8=mean(PFUperml), stdev8=sd(PFUperml)) 
>  
> #calculate percentages 
> final8 <- filter(grouped8, Replicate==1, SampleDilutionN==2) 
>  
> #Calculating Log losses in titer 
> #Calculate  Logarithms 0h-121h 
> groupedlog8<- final8%>% 
+   group_by(Time, Name) %>% 
+   mutate(avglog8=log10(avg8), stdevlog8=(log10(avg8+stdev8)-log10(avg8-
stdev8))/2) 
>  
> #Calculate Differences 
> finallog8 <- groupedlog8 %>% 
+   group_by(Name) %>% 
+   mutate(logdiff8= (-1)*(avglog8-log10(avg8[Time==0])), 






> study8logdiff <- filter(finallog8, Time>110) 
 
> #Chapter 5 Plots (5.3-4) [FBS] (Study 8)----------------------------- 
>  
> plotJ <- final8 
>                  
> plotlogJ <- study8logdiff 
>  
> #PFU vs. Time 
> J1<-ggplot(plotJ, aes(x=Time, y=avg8, linetype=factor(Buffer)))+ 
+   labs(x="\nTime (h)", y="Viral titer (PFU/ml)\n")+ 
+   geom_line(aes(y=avg8), size=0.25)+  
+   geom_point(aes(Time, avg8, shape=factor(Buffer)), size=2.5)+ 
+   scale_y_continuous(labels=function(n){format(n, scientific = TRUE)})+ 
+   scale_y_continuous(labels=fancy_scientific)+ 
+   scale_linetype_discrete(breaks=c("Sanofi Buffer", "Sanofi Buffer FBS 
50%", "Sanofi Buffer FBS 10%", "Sanofi Buffer FBS 1%", "Sanofi Buffer FBS 
0.1%", "Sanofi Buffer FBS 0.01%"), 
+                           labels=c("Reference Buffer", "+50% FBS", "+10% 
FBS", "+1% FBS", "+0.1% FBS", "+0.01% FBS"), 
+                           name="Buffer")+ 
+   scale_shape_discrete(breaks=c("Sanofi Buffer", "Sanofi Buffer FBS 
50%", "Sanofi Buffer FBS 10%", "Sanofi Buffer FBS 1%", "Sanofi Buffer FBS 
0.1%", "Sanofi Buffer FBS 0.01%"), 
+                        labels=c("Reference Buffer", "+50% FBS", "+10% 
FBS", "+1% FBS", "+0.1% FBS", "+0.01% FBS"), 
+                        name="Buffer")+ 
+   theme(text=element_text(size=11), 
legend.title=element_text(face="bold"), axis.text.x=element_text(size=11), 
+         axis.title=element_text(face="bold"), 
strip.text=element_text(face="bold"), 
axis.ticks=element_line(color="gray97"), 
+         strip.background=element_rect(fill="gray97"), 
panel.background=element_rect(fill="white"),panel.margin.x=unit(0.3, 
"in"), 
+         panel.grid.major=element_line(colour="gray90"), 
panel.grid.minor=element_line(colour="gray97")) +  
+   geom_errorbar(aes(ymin = avg8-stdev8, ymax = avg8+stdev8), width=2, 
size=0.25) 
Scale for 'y' is already present. Adding another scale for 'y', which will 
replace the existing scale. 
Warning messages: 
1: `panel.margin` is deprecated. Please use `panel.spacing` property 
instead  
2: `panel.margin.x` is deprecated. Please use `panel.spacing.x` property 
instead  
> ggsave("//Users//juliamanalil//Dropbox/Aucoin 
Lab//Thesis//Figures//v3//5.3A.jpg", plot=J1, dpi=300, width=6, 
height=3.5) 
>  
> #log loss in titer after 120h 
> J2<-ggplot(plotlogJ, aes(factor(Buffer), logdiff8)) + 
+   labs(x="Buffer",y="Log loss in titer after 120h\n") + 
+   geom_bar(stat="identity", colour="black", fill="gray97", size=0.25) + 
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+   annotate("text", x=c(2,3,4,5), y=c(0.53, 0.41, 0.33, 0.39), 
label=c("*", "*", "*", "*"), size=5)+ 
+   scale_x_discrete(breaks=c("Sanofi Buffer", "Sanofi Buffer FBS 50%", 
"Sanofi Buffer FBS 10%", "Sanofi Buffer FBS 1%", "Sanofi Buffer FBS 0.1%", 
"Sanofi Buffer FBS 0.01%"), 
+                    labels=c("Reference Buffer", "+50% FBS", "+10% FBS", 
"+1% FBS", "+0.1% FBS", "+0.01% FBS"))+ 
+   theme(text=element_text(size=11), 
legend.title=element_text(face="bold"), axis.text.x=element_text(angle=30, 
hjust=1, size=11, colour="black"), 
+         axis.title=element_text(face="bold"), 
strip.text=element_text(face="bold"), 
axis.ticks=element_line(color="gray97"), 
+         strip.background=element_rect(fill="gray97"), 
panel.background=element_rect(fill="white"),panel.margin.x=unit(0.3, 
"in"), 
+         panel.grid.major.y=element_line(colour="gray90"), 
panel.grid.minor.y=element_line(colour="gray97")) +  
+   geom_errorbar(aes(ymin = logdiff8-logdiffstdev8, ymax = 
logdiff8+logdiffstdev8), width = 0.2, size=0.25) 
Warning messages: 
1: `panel.margin` is deprecated. Please use `panel.spacing` property 
instead  
2: `panel.margin.x` is deprecated. Please use `panel.spacing.x` property 
instead  
> ggsave("//Users//juliamanalil//Dropbox/Aucoin 
Lab//Thesis//Figures//v3//5.3B.jpg", plot=J2, dpi=300, width=3, 
height=3.5) 
>  
> JFinB<-plot_grid(J2, NULL, nrow=1) 
> JFin<-plot_grid(J1, JFinB, nrow=2, labels=c('A', 'B'), rel_heights = 
c(5,6)) 
> ggsave("//Users//juliamanalil//Dropbox/Aucoin 
Lab//Thesis//Figures//v3//5.3.jpg", plot=JFin, dpi=300, width=7, height=8) 
>  
> #Modelling 
> SBS507278<-filter(final8, Name=="8S50SB7.27") 
> SBS107278<-filter(final8, Name=="8S10SB7.27") 
> SBS17278<-filter(final8, Name=="8S1SB7.27") 
> SBS0.17278<-filter(final8, Name=="8S0.1SB7.27") 
> SBS0.017278<-filter(final8, Name=="8S0.01SB7.27") 
> SB7278<-filter(final8, Name=="8SB7.27") 
>  
> #add xlabs, fix theme 
> xlabs8<-c('Sanofi Buffer'="Reference Buffer",  
+            'Sanofi Buffer FBS 50%'="+ 50% FBS",  
+            'Sanofi Buffer FBS 10%'="+ 10% FBSA", 
+            'Sanofi Buffer FBS 1%'="+ 1% FBS", 
+           'Sanofi Buffer FBS 0.1%'="+ 0.1% FBS", 
+           'Sanofi Buffer FBS 0.01%'="+ 0.01% FBS") 
> J3<-ggplot(final8, aes(x=Time, y=avg8))+ 
+   labs(x="\nTime (h)", y="Viral titer (PFU/ml)\n")+ 
+   geom_point(aes(Time, avg8), size=0.25)+ 
+   facet_wrap(~Buffer, ncol=2,labeller=as_labeller(xlabs8))+ 
+   scale_y_continuous(labels=function(n){format(n, scientific = TRUE)})+ 
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+   scale_y_continuous(labels=fancy_scientific)+ 
+   theme(text=element_text(size=16), 
legend.title=element_text(face="bold"), 
axis.text.x=element_text(colour="black", size=16), 
+         axis.title=element_text(face="bold"), 
strip.text=element_text(face="bold"), 
axis.ticks=element_line(color="gray97"), 
+         strip.background=element_rect(fill="gray97"), 
panel.background=element_rect(fill="white"),panel.margin.x=unit(0.3, 
"in"), 
+         panel.grid.major=element_line(colour="gray90"), 
panel.grid.minor=element_line(colour="gray97")) +  
+   geom_errorbar(aes(ymin = avg8-stdev8, ymax = avg8+stdev8), width = 2, 
size=0.25, position="dodge")+ 
+   scale_linetype_discrete(name="Model")+ 
+   geom_smooth(method="nls", aes(linetype = 'Exponential'), 
#color="black",  
+               formula='y~e*exp(-f*x)', 
+               method.args=list(start=c(e=2e7, f=0)), size=0.5, 
se=FALSE)+ # 
+   geom_smooth(method="lm", aes(linetype = 'Linear'),size=0.5, 
#color="black",  
+               formula='y~x') 
Scale for 'y' is already present. Adding another scale for 'y', which will 
replace the existing scale. 
Warning messages: 
1: `panel.margin` is deprecated. Please use `panel.spacing` property 
instead  
2: `panel.margin.x` is deprecated. Please use `panel.spacing.x` property 
instead  
> ggsave("//Users//juliamanalil//Dropbox/Aucoin 





> mSB7278<-nls(y~(e*exp(-f*x)), data = SB7278, start = list(e=2e7, f = 0)) 
Warning messages: 
1: In min(x) : no non-missing arguments to min; returning Inf 
2: In max(x) : no non-missing arguments to max; returning -Inf 
> summary(mSB7278) 
 
Formula: y ~ (e * exp(-f * x)) 
 
Parameters: 
   Estimate Std. Error t value Pr(>|t|)    
e 1.704e+05  5.730e+03   29.73  0.00113 ** 
f 1.271e-02  1.043e-03   12.19  0.00667 ** 
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Residual standard error: 6406 on 2 degrees of freedom 
 
Number of iterations to convergence: 8  











lm(formula = y ~ x, data = SB7278) 
 
Residuals: 
     1      2      3      4  
 16054 -11584 -16712  12242  
 
Coefficients: 
            Estimate Std. Error t value Pr(>|t|)    
(Intercept) 157570.7    15577.7  10.115  0.00963 ** 
x            -1048.0      218.1  -4.805  0.04069 *  
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Residual standard error: 20260 on 2 degrees of freedom 
Multiple R-squared:  0.9203, Adjusted R-squared:  0.8804  
F-statistic: 23.09 on 1 and 2 DF,  p-value: 0.04069 
 
>  
> #0.01% FBS 
> y=SBS0.017278$avg8 
> x=SBS0.017278$Time 
> mSBS0.017278<-nls(y~(e*exp(-f*x)), data = SBS0.017278, start = 
list(e=2e7, f = 0)) 
Warning messages: 
1: In min(x) : no non-missing arguments to min; returning Inf 
2: In max(x) : no non-missing arguments to max; returning -Inf 
> summary(mSBS0.017278) 
 
Formula: y ~ (e * exp(-f * x)) 
 
Parameters: 
   Estimate Std. Error t value Pr(>|t|)    
e 1.811e+05  6.711e+03  26.985  0.00137 ** 
f 8.973e-03  8.986e-04   9.986  0.00988 ** 
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Residual standard error: 7772 on 2 degrees of freedom 
 
Number of iterations to convergence: 6  











lm(formula = y ~ x, data = SBS0.017278) 
 
Residuals: 
        1         2         3         4  
  7083.33    -87.11 -17319.06  10322.83  
 
Coefficients: 
            Estimate Std. Error t value Pr(>|t|)    
(Intercept) 173202.4    11617.7  14.909  0.00447 ** 
x             -963.1      162.7  -5.921  0.02736 *  
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Residual standard error: 15110 on 2 degrees of freedom 
Multiple R-squared:  0.946, Adjusted R-squared:  0.919  
F-statistic: 35.05 on 1 and 2 DF,  p-value: 0.02736 
 
>  
> #0.1% FBS 
> y=SBS0.17278$avg8 
> x=SBS0.17278$Time 
> mSBS0.17278<-nls(y~(e*exp(-f*x)), data = SBS0.17278, start = list(e=2e7, 
f = 0)) 
Warning messages: 
1: In min(x) : no non-missing arguments to min; returning Inf 
2: In max(x) : no non-missing arguments to max; returning -Inf 
> summary(mSBS0.17278) 
 
Formula: y ~ (e * exp(-f * x)) 
 
Parameters: 
   Estimate Std. Error t value Pr(>|t|)     
e 2.031e+05  9.579e+02  212.01 2.22e-05 *** 
f 5.685e-03  9.220e-05   61.65 0.000263 *** 
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Residual standard error: 1151 on 2 degrees of freedom 
 
Number of iterations to convergence: 5  









lm(formula = y ~ x, data = SBS0.17278) 
 
Residuals: 
    1     2     3     4  
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 3024 -2014 -3481  2471  
 
Coefficients: 
             Estimate Std. Error t value Pr(>|t|)     
(Intercept) 199531.26    3047.37   65.48 0.000233 *** 
x             -834.04      42.67  -19.55 0.002607 **  
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Residual standard error: 3964 on 2 degrees of freedom 
Multiple R-squared:  0.9948, Adjusted R-squared:  0.9922  
F-statistic:   382 on 1 and 2 DF,  p-value: 0.002607 
 
>  
> #1% FBS 
> y=SBS17278$avg8 
> x=SBS17278$Time 
> mSBS17278<-nls(y~(e*exp(-f*x)), data = SBS17278, start = list(e=2e7, f = 
0)) 
Warning messages: 
1: In min(x) : no non-missing arguments to min; returning Inf 
2: In max(x) : no non-missing arguments to max; returning -Inf 
> summary(mSBS17278) 
 
Formula: y ~ (e * exp(-f * x)) 
 
Parameters: 
   Estimate Std. Error t value Pr(>|t|)     
e 2.049e+05  5.014e+03   40.86 0.000599 *** 
f 4.301e-03  4.384e-04    9.81 0.010232 *   
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Residual standard error: 6130 on 2 degrees of freedom 
 
Number of iterations to convergence: 6  









lm(formula = y ~ x, data = SBS17278) 
 
Residuals: 
    1     2     3     4  
-2238  1516  2524 -1803  
 
Coefficients: 
             Estimate Std. Error t value Pr(>|t|)     
(Intercept) 203237.77    2236.79   90.86 0.000121 *** 




Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Residual standard error: 2909 on 2 degrees of freedom 
Multiple R-squared:  0.996, Adjusted R-squared:  0.994  
F-statistic: 496.8 on 1 and 2 DF,  p-value: 0.002007 
 
>  
> #10% FBS 
> y=SBS107278$avg8 
> x=SBS107278$Time 
> mSBS107278<-nls(y~(e*exp(-f*x)), data = SBS107278, start = list(e=2e7, f 
= 0)) 
Warning messages: 
1: In min(x) : no non-missing arguments to min; returning Inf 
2: In max(x) : no non-missing arguments to max; returning -Inf 
> summary(mSBS107278) 
 
Formula: y ~ (e * exp(-f * x)) 
 
Parameters: 
   Estimate Std. Error t value Pr(>|t|)    
e 1.985e+05  7.657e+03  25.921  0.00148 ** 
f 5.246e-03  7.333e-04   7.154  0.01899 *  
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Residual standard error: 9249 on 2 degrees of freedom 
 
Number of iterations to convergence: 6  









lm(formula = y ~ x, data = SBS107278) 
 
Residuals: 
    1     2     3     4  
-4056  3283  3518 -2744  
 
Coefficients: 
             Estimate Std. Error t value Pr(>|t|)     
(Intercept) 196500.92    3732.54   52.65 0.000361 *** 
x             -791.93      52.26  -15.15 0.004327 **  
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Residual standard error: 4855 on 2 degrees of freedom 
Multiple R-squared:  0.9914, Adjusted R-squared:  0.987  





> #50% FBS 
> y=SBS507278$avg8 
> x=SBS507278$Time 
> mSBS507278<-nls(y~(e*exp(-f*x)), data = SBS507278, start = list(e=2e7, f 
= 0)) 
Warning messages: 
1: In min(x) : no non-missing arguments to min; returning Inf 
2: In max(x) : no non-missing arguments to max; returning -Inf 
> summary(mSBS507278) 
 
Formula: y ~ (e * exp(-f * x)) 
 
Parameters: 
   Estimate Std. Error t value Pr(>|t|)    
e 1.941e+05  1.539e+04  12.608  0.00623 ** 
f 9.635e-03  2.009e-03   4.795  0.04085 *  
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Residual standard error: 17710 on 2 degrees of freedom 
 
Number of iterations to convergence: 7  









lm(formula = y ~ x, data = SBS507278) 
 
Residuals: 
    1     2     3     4  
-6916 12440 -7548  2024  
 
Coefficients: 
            Estimate Std. Error t value Pr(>|t|)    
(Intercept) 188665.8     8827.3   21.37  0.00218 ** 
x            -1160.7      123.6   -9.39  0.01115 *  
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Residual standard error: 11480 on 2 degrees of freedom 
Multiple R-squared:  0.9778, Adjusted R-squared:  0.9667  




Effects of FBS and PF68: Replicate ACAM529 stability studies 
The following figures show the results of replicate stability studies of ACAM529 with 10% or 1% 
FBS, or 0.05% or 0.1% PF68. Each figure is a separate experiment and includes run-specific details. 
 
 
Figure G.1 Effect of 10% FBS on ACAM529 stability. 
Frozen virus Lot B was quickly thawed at 37°C and diluted 1/100 in triplicate into freshly prepared 
reference buffer at pH 7 with or without 10% (v/v) FBS, then incubated at 27°C. Samples were taken 
immediately after (0 hour), 24, 72, and 120 hours after diluting the virus to monitor the viral titer 
using plaque assays and titers were reported as PFU/ml (A). The total log loss in titer (B) was 





Figure G.2 Effect of 1% FBS on ACAM529 stability. 
Frozen virus Lot B was quickly thawed at 37°C and diluted 1/100 in triplicate into freshly prepared 
reference buffer at pH 7 with or without 1% (v/v) FBS, then incubated at 27°C. Samples were taken 
immediately after (0 hour), 4, 8, 16, 24, 48, 72, and 120 hours after diluting the virus to monitor the 
viral titer using plaque assays and titers were reported as PFU/ml (A). The total log loss in titer (B) 






Figure G.3 Effect of 0.05% and 0.1% PF68 on ACAM529 stability: Replicate 1. 
Frozen virus Lot B was quickly thawed at 37°C and diluted 1/100 in triplicate into freshly prepared 
reference buffer at pH 7 with or without 0.05% or 0.1% (w/v) PF68, then incubated at 27°C. Samples 
were taken immediately after (0 hour) and 120 hours after diluting the virus to monitor the viral titer 
using plaque assays and titers were reported as PFU/ml (A). The total log loss in titer (B) was 





Figure G.4 Effect of 0.1% PF68 on ACAM529 stability: Replicate 2. 
Frozen virus Lot B was quickly thawed at 37°C and diluted 1/100 in triplicate into freshly prepared 
reference buffer at pH 7 with or without 0.1% (w/v) PF68, then incubated at 27°C. Samples were 
taken immediately after (0 hour) and 120 hours after diluting the virus to monitor the viral titer using 
plaque assays and titers were reported as PFU/ml (A). The total log loss in titer (B) was determined 




Additional ACAM529 stability studies 
H.1 Povidone as an excipient 
Polyvinylpyrrolidone or povidone is used commonly for pharmaceuticals for its adhesive, film-
forming, dispersing, and thickening properties. It is used as a tablet binding and sugar coating agent, 
solubilizer, and stabilizer. It has reportedly been used to stabilize enzymes by forming a complex such 
as with asparaginase, beta-interferon, catalase, pyruvate carboxylase, peroxidase, and urease 146. 
Povidone has also been used as a shear protectant in cell culture so it may possess desirable properties 
for stabilizing ACAM529. Shear protectants are employed in cell culture for the purposes of 
protecting membranes from harsh hydrodynamic forces, and it may be able to offer stability to the 
ACAM529 membrane.  
H.1.1 Materials and methods 
Frozen virus Lot B was quickly thawed at 37°C and diluted 1/100 in triplicate into freshly prepared 
reference buffer at pH 7 with or without 0.1%, 1%, and 10% (w/v) povidone (Sigma-Aldrich), then 
incubated at 27°C. For the stability study investigating the interaction effect between povidone and 
rHSA, frozen Lot A virus was quickly thawed at 37°C and diluted 1/100 in triplicate into the 
following freshly prepared buffers: reference buffer at pH 7; reference buffer at pH 7 with 0.1% (w/v) 
povidone; reference buffer at pH 7 with 0.1% (w/v) povidone and 2 g/L rHSA (Cellastim, Invitria); 
and reference buffer at pH 7 with 2 g/L rHSA, then incubated at 27°C. For both experiments, samples 
were taken immediately after (0 hour), and 120 hours after diluting the virus to monitor the viral titer 
using plaque assays as described previously in Chapter 3.  
H.1.2 Results 
To test whether povidone stabilizes ACAM529, virus Lot B was diluted in the reference buffer with 
the addition of 0.1%, 1% and 10% (w/v) povidone and incubated at 27°C for 120h. Initial viral titers 
at 0h were similar with or without povidone at all concentrations except with 10% povidone, which 
showed a slight decrease in titer (Figure H.1A). After 120h, increasing concentrations of povidone 
resulted in increasingly larger losses in viral titer, with concentrations above 0.1% leading to 
significantly lower viral titers compared to the control with no povidone (Figure H.1B). The addition 
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of 10% povidone lead to a log loss in titer three times larger than the control. The presence of 0.1% 
povidone did not significantly affect the initial titer or the overall log loss in titer after 120h when 
compared to the control with no povidone. 
In order to investigate whether there was an interaction event between rHSA and povidone, 
ACAM529 was incubated in the reference buffer containing 2 g/L rHSA and 0.1% povidone for 120 
hours at 27°C and the results are presented in Figure H.2. The log loss in titer of the virus in the 
buffer containing povidone and rHSA was 1.19 ± 0.10, which was not significantly different from 
that of the virus in the reference buffer with 2 g/L rHSA (1.13 ± 0.08). Povidone did not have any 
interaction effect on viral stability with rHSA but instead, the same significant reduction in stability 
with the addition of rHSA seen in section 5.3.2 was observed here. 
H.1.3 Conclusion 
Povidone did not significantly affect the infectivity or the overall stability of ACAM529 after 120h at 
concentrations used in cell culture (0.1%). Also, 0.1% povidone did not have any interaction effect 
with 2 g/L rHSA in stabilizing ACAM529. However, the presence of 1-10% povidone lead to 





Figure H.1 Effect of different concentrations of povidone on ACAM529 stability. 
ACAM529 Lot B was diluted into the reference buffer with or without 0.1%, 1%, or 10% povidone 
and incubated at 27°C for 120h. Viral titer at 0h and 120h was quantified using plaque assays and 
reported as PFU/ml (A). The total log loss in titer (B) was determined and a significant deviation (α = 





Figure H.2 Effects of povidone and rHSA on ACAM529 stability.  
ACAM529 Lot A was diluted into the reference buffer with or without 0.1% povidone, or 2 g/L 
rHSA, or 0.1% povidone and 2 g/L rHSA, then incubated at 27°C for 120h. Viral titer at 0h and 120h 
was quantified using plaque assays and reported as PFU/ml (A). The total log loss in titer (B) was 




H.2 Effects of whole buffer formulations: Assaying HSV-2 lyophilization buffer 
One of the most damaging processes to lipid membranes is freeze-drying and extensive research has 
gone into developing strategies and libraries of excipients that will protect biological products from 
such damage 55,59,74. Cantab Pharmaceuticals Research Ltd. owns a 2001 patent (US 6258362 B1 147) 
for stabilization formulations for herpesvirus, more specifically, a disabled HSV-2 vaccine. It 
describes several formulations that claim to retain within 0.5 log of the starting titer of a lyophilized 
sample after a period ranging from 16-52 weeks at 8°C. Here, two representative example buffers 
presented in the patent were screened for stabilizing properties for ACAM529 
H.2.1 Materials and methods 
ACAM529 Lot A was quickly thawed at 37°C and diluted 1/100 into freshly prepared reference 
buffer at pH 7, Cantab Pharmaceuticals buffer Example 1 (CP1) (5% (w/v) lactose (Sigma-Aldrich), 
5% (w/v) sucrose (Sigma-Aldrich), 1.8% (w/v) sorbitol (Sigma-Aldrich), 0.1% (w/v) sodium 
glutamate (Sigma-Aldrich), 2% (w/v) vegetable peptone, 0.1 M Tris-HCl (Bio-Rad), pH 7), or Cantab 
Pharmaceuticals buffer Example 2 (CP2) (2.5% (w/v) sucrose, 0.5% (w/v) sodium glutamate, 2.5% 
(w/v) dextran (MW 9,000 - 11,000) (Sigma-Aldrich), 0.1 M Tris-HCl, pH 7), then incubated at room 
temperature. Samples were taken in triplicate immediately after (0 hour), and 2, 10, 24, 48, 72, 96, 
and 120 hours after diluting the virus to monitor the viral titer using plaque assays as described in 
Chapter 3.  
H.2.2 Results 
Two representative variations of the Cantab Pharmaceutical’s patented formulation with components 
of interest were assayed for stabilization of ACAM529 at room temperature using a time course 
assay. The Cantab buffers demonstrated sharper decreases in viral stability over the first 48 hours 
when compared to the control (Figure H.3A). CP2 had a higher titer loss after 120 hours compared to 
CP1, at 0.72 ± 0.04 log compared to 0.61 ± 0.08 log loss in titer, respectively, but both were 
significantly higher than the control, which only had a 0.40 ± 0.09 log loss in titer (Figure H.3B). The 
combination of components of the Cantab buffers was insufficient for stabilizing ACAM529 in liquid 





Figure H.3 Effect of two sample formulations for a lyophilized HSV-2 vaccine on ACAM529 
stability.  
ACAM529 LOT A was diluted into either the reference buffer, Cantab Pharmaceuticals Example 
buffer 1 (CP1), or Cantab Pharmaceuticals Example buffer 2 (CP2), then incubated at room 
temperature. Viral stability over time was monitored using plaque assays and reported as PFU/ml (A). 
The total log loss in titer (B) was determined and buffers which yielded a significant deviation (α = 




The Cantab buffers are optimized for lyophilized HSV and its stabilizing effects may not be sufficient 
for virus in liquid form. The lyophilization process significantly reduces the moisture levels around 
the product so formulations would aim to mitigate the negative effects by providing excipients that 
would take the place of water molecules on the product surface 57. Also, the product would experience 
less motility in the lyophilized form and would not be subjected to the same deleterious pathways it 
would encounter in liquid solution so it would not always require the same type of stabilizers. The 
glutamate level in CP1 was two orders of magnitude lower than that in the reference buffer, and one 
order of magnitude lower than that in CP2. Also CP2, which had the worst stabilizing properties, had 
half the amount of sugars (by weight) compared to CP1 and the reference buffer. Furthermore, Tris 
buffers have been known to have difficulty with pH fluctuations during freezing steps56,58 yet it is 
listed as a component of Cantabs formulation buffer. It is clear that formulations that stabilize one 
type of biological do not necessarily stabilize another, which makes developing formulations a 
challenge.  
Nevertheless, there are components of the Cantab buffers that are of interest to study further. For 
example, sorbitol, found in CP1, is a sugar alcohol that is not easily crystalized and acts as a 
plasticizer, increasing mobility but improving stability 56. Sorbitol and gelatin formulations are 
effective for many vaccines 55. Dextran, used in CP2, is a hygroscopic polysaccharide made up of 
glucose monomers and it is able to increase solution viscosity. It is used commonly for lyophilization 
as it acts as a bulking agent and lyoprotectant 148. Despite the Cantab buffers performing poorly in 
these studies, the potential stabilization properties of the components can not be completely ruled out. 
Controlled studies where excipients are added to the ACAM529 base purification buffer would 
provide better information as to whether the excipient is contributing to the stabilization of the virus. 
 
